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Summary 
Asthma is a complex airway disease with many different underlying mechanisms. 
Therefore it tends to be considered as a syndrome containing several subtypes 
sharing important similarities but also displaying differences caused by variable 
aetiologies. We propose that a phenotype should be comprised of those clinical 
characteristics of a disease that have prognostic or therapeutic implications that are 
disease-specific. The classification of asthmatics in different inflammatory 
phenotypes according to induced sputum cell count has already been shown to 
predict the response to targeted therapy.  
 
In the first part of this work, we have confirmed on a large unselected asthmatic 
cohort the heterogeneity of airway inflammation and provided the distribution of each 
inflammatory phenotype as encountered in patients seen in a university hospital. The 
most frequently observed inflammatory subtypes were eosinophilic and 
paucigranulocytic phenotypes. The same approach for severe asthmatics showed 
that the proportion of paucigranulocytic asthma was very low in this subgroup, 
supporting the role of uncontrolled airway inflammation as a key factor in determining 
asthma severity.  
 
In the second part of this thesis, we described the demographic, functional and 
inflammatory characteristics of the different inflammatory phenotypes. We showed 
that eosinophilic asthma was more prone to exacerbations.  
 
In the third part, we have shown that factors associated with airway eosinophilic differ 
from those associated with airway neutrophilic phenotype. Independent predictors of 
20 
 
eosinophilic asthma were blood eosinophils, elevated FENO levels, high serum IgE 
levels and low FEV1/FVC ratio while for neutrophilic asthma we found higher FRC 
and age. We have been able to show that FENO and blood eosinophil thresholds 
that predict airway eosinophilic inflammation may be influenced by the dose of 
inhaled corticosteroids and smoking history for the former. We have also found that 
Volatile Organic Compounds are able to discriminate between airway eosinophilic 
and neutrophilic inflammatory cell types. 
 
In the fourth part of this work, we have evaluated the value of exhaled nitric oxide as 
a marker of airway hyperresponsiveness. We have shown that FENO measurement 
may be useful in diagnosing asthma in patients with chronic respiratory symptoms in 
whom bronchodilation test failed or was not appropriate to demonstrate asthma. In 
this pre-specified asthma population, the value of FENO essentially lies in its high 
specificity, and a FENO level lower than the best threshold (34ppb) should prompt 
the clinician to ask for a methacholine challenge to confirm asthma diagnosis. 
 
In the fifth part of this thesis we have proposed a new way to classify asthma based 
on compartmental eosinophilic inflammation. By looking simultaneously at blood and 
sputum eosinophil count we have identified a subgroup of asthmatics exhibiting both 
blood and airway eosinophilic inflammation. This subgroup included a majority of 
males, had lower asthma control, poorer lung function and was more prone to 
exacerbation. With respect to co-morbidities, this group also had nasal polyposis 
more often. We believe our new classification may be useful as we now have 
available treatments targeting either airway (ICS) or systemic (OCS, anti-IL5) 
eosinophilic inflammation.  
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Conclusion 
It is becoming increasingly clear that classification of asthmatics according to various 
inflammatory phenotypes will guide the choice of treatment. Induced sputum is the 
gold standard non-invasive tool for inflammatory phenotyping. We have provided 
evidence that this technique may be routinely applied in a university centre. We have 
also proposed a new classification of inflammatory phenotypes based on blood and 
airway eosinophilia, a classification which identified a subgroup of patients with 
diffuse eosinophilic inflammation with poor asthma control and higher risk of 
exacerbation. As we understand induced sputum may never be applied in primary or 
some secondary care settings we have also identified surrogate markers for 
inflammatory phenotypes.   
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Résumé 
L'asthme est une maladie complexe des voies respiratoires avec de nombreux 
mécanismes sous-jacents. Pour cette raison, l’asthme est souvent considéré comme 
un syndrome avec plusieurs sous-types partageant des similitudes importantes mais 
également des différences liées à des étiologies variables. Nous proposons que 
chaque phénotype corresponde à un ensemble de caractéristiques cliniques d'une 
maladie qui a des implications pronostiques ou thérapeutiques et qui est spécifique 
de cette pathologie. La classification des asthmatiques en différents phénotypes 
inflammatoires en fonction du nombre de cellules présentes dans l’expectoration 
induite a prouvé son efficacité dans la prédiction de la réponse à une thérapie ciblée.  
 
Dans la première partie de ce travail, nous avons confirmé l'hétérogénéité de 
l'inflammation des voies aériennes sur une large cohorte d'asthmatiques non 
sélectionnés. Nous avons également présenté la distribution de chaque phénotype 
inflammatoire sachant que les patients étudiés ont été recrutés dans un hôpital 
universitaire. Les sous-types inflammatoires les plus fréquemment observés sont le 
phénotype éosinophilique et paucigranulocytique. Nous avons utilisé la même 
approche pour les asthmatiques sévères et avons observé que la proportion 
d'asthmatiques paucigranulocytiques était très faible dans ce sous-groupe. Cette 
observation renforce le rôle de l'inflammation non contrôlée des voies aériennes 
comme facteur clé dans la détermination de la sévérité de l'asthme.  
 
Dans la deuxième partie de cette thèse, nous avons décrit les caractéristiques 
démographiques, fonctionnelles et inflammatoires des différents phénotypes 
inflammatoires. Nous avons montré que l'asthme éosinophilique était plus enclin aux 
24 
 
exacerbations.  
 
Dans la troisième partie, nous avons montré que les facteurs associés à 
l’inflammation éosinophilique des voies respiratoires diffèrent de ceux associés au 
phénotype neutrophilique. Les facteurs prédictifs indépendants de l'asthme 
éosinophilique étaient les éosinophiles sanguins, un taux élevé de FENO, des taux 
d'IgE sériques élevés et un faible rapport VEMS/CVF tandis que pour l'asthme 
neutrophilique les facteurs de prédiction étaient une capacité résiduelle fonctionnelle 
plus élevée et un âge plus avancé. Nous avons pu montrer que les seuils de FENO 
et d’éosinophiles sanguins qui permettent de prédire l'inflammation éosinophilique 
peuvent être influencés par la dose de corticoïdes inhalés et les antécédents de 
tabagisme pour le FENO. Nous avons également trouvé que les composés 
organiques volatiles sont capables de discriminer le phénotype éosinophilique du 
neutrophilique.  
 
Dans la quatrième partie de ce travail, nous avons évalué la valeur du monoxyde 
d’azote exhalé comme marqueur de l’hyperréactivité bronchique. Nous avons montré 
que la mesure du FENO peut être utile dans le diagnostic de l'asthme chez les 
patients présentant des symptômes respiratoires chroniques pour lesquels un test de 
bronchodilatation a échoué à démontrer l'asthme ou n’était pas approprié vu des 
valeurs spirométriques de base supranormales. Dans cette population spécifique 
d’asthmatique, la valeur du FENO tient surtout à sa spécificité élevée mais une 
valeur de FENO inférieure à 34ppb devrait convaincre le clinicien de demander un 
test de provocation à la méthacholine pour confirmer la pathologie asthmatique.  
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Dans la cinquième partie de cette thèse, nous avons proposé une nouvelle façon de 
classer l'asthme, basée sur la compartimentalisation de l’inflammation 
éosinophilique. En regardant simultanément le nombre d’éosinophiles du sang et des 
expectorations, nous avons identifié un sous-groupe d'asthmatiques présentant à la 
fois une inflammation éosinophilique systémique et bronchique. Ce sous-groupe 
incluait une majorité d’hommes, avait le moins bon contrôle de l'asthme, la fonction 
pulmonaire la plus mauvaise et était plus enclin à présenter des exacerbations. En ce 
qui concerne les comorbidités, ce groupe présentait aussi plus souvent de la 
polypose nasale. Nous pensons que notre nouvelle classification peut être utile vu la 
disponibilité de traitements ciblant l’inflammation éosinophilique des voies aériennes 
(CSI) ou systémique (CSO, anti-IL5).  
 
Conclusion  
Il est de plus en plus évident que la classification des asthmatiques selon divers 
phénotypes inflammatoires guidera le choix du traitement. L’analyse de 
l’expectoration induite est l'outil non invasif de choix pour le phénotypage 
inflammatoire. Nous avons apporté la preuve que cette technique peut être appliquée 
en routine dans un centre universitaire. Nous avons également proposé une nouvelle 
classification des phénotypes inflammatoires sur base de l’éosinophilie des voies 
aérienne et systémique, une classification qui a permis d’identifier un sous-groupe de 
patients présentant une inflammation éosinophilique diffuse avec un mauvais 
contrôle de l'asthme et un risque plus élevé d'exacerbation. Comme nous sommes 
conscients du fait que la technique de l'expectoration induite ne pourra jamais être 
appliquée en pratique clinique dans les centres non universitaires, nous avons 
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également identifié des marqueurs de substitution pour l’identification des 
phénotypes inflammatoires.   
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Samenvatting 
Astma is een complexe luchtwegaandoening met veel verschillende onderliggende 
mechanismen. Daarom wordt astma vaak beschouwd als een syndroom bestaande 
uit meerdere subtypes die enerzijds belangrijke overeenkomsten vertonen maar 
anderzijds ook belangrijke verschillen, die geassocieerd zijn met de verscheidenheid 
in de ontstaansmechanismen. Wij stellen voorop dat elk astma fenotype zou moeten 
bestaan uit een reeks klinische kenmerken van de ziekte die een prognostische of 
therapeutische waarde hebben, en die ziektespecifiek zijn.  
Er werd reeds aangetoond dat de classificatie van astma patiënten in verschillende 
inflammatoire fenotypes op basis van de cellulaire samenstelling van het 
geïnduceerd sputum de reactie op een gerichte therapie kan voorspellen. 
 
In het eerste deel van dit proefschrift, hebben we de heterogeniteit van de 
luchtweginflammatie bevestigd op een grote cohorte van ongeselecteerde 
astmapatiënten en hebben we de distributie van elk inflammatoire fenotype 
beschreven, zoals deze werd waargenomen bij de patiënten die werden gerekruteerd 
in een universitair ziekenhuis. De meest frequent geobserveerde inflammatoire 
subtypes waren het eosinofiele en het paucigranulocitaire fenotype. 
Wanneer dezelfde onderzoeksbenadering werd gebruikt bij ernstig astmapatiënten 
bleek dat het aandeel van paucigranulocytic astma heel laag was in deze subgroep. 
Deze observatie versterkt de rol van ongecontroleerde luchtweginflammatie als 
bepalende factor in de ernst van astma.  
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In een tweede deel van dit proefschrift beschreven we de demografische, functionele 
en inflammatoire kenmerken van de verschillende inflammatoire fenotypes. We 
toonden aan dat eosinofiel astma meer gevoelig is voor exacerbaties. 
 
In een derde deel, hebben we aangetoond dat de factoren die geassocieerd zijn met 
eosinofiele luchtweginflammatie verschillend zijn van deze die geassocieerd zijn met 
het neutrofiele fenotype. Onafhankelijke predictors van eosinofiel astma waren 
bloedeosinofielen, verhoogde FENO waarden, hoge niveaus van serum IgE en een 
lage FEV1/FVC verhouding. Voor neutrofiel astma was dit hogere FRC en hogere 
leeftijd.  
We konden aantonen dat de drempelwaarden voor bloedeosinofielen en FENO,  die 
een eosinofilie luchtweginflammatie voorspellen, beïnvloed kunnen worden door de 
dosis inhalatiecorticosteroïden. De FENO waarden worden ook beïnvloed door de 
rookgeschiedenis. We konden eveneens aantonen dat er een onderscheid kan 
gemaakt worden tussen eosinofiele en neutrofiele fenotype op basis van vluchtige 
organische componenten in de uitgeademde lucht.  
 
In een vierde deel van dit proefschrift, hebben we de waarde van uitgeademd 
stikstofoxide als merker van luchtweghyperresponsiviteit geëvalueerd. 
We toonden aan dat FENO bepalingen nuttig kunnen zijn in de diagnose van astma 
bij patiënten met chronische respiratoire symptomen waarbij de bronchodilatortest 
mislukte of niet van toepassing was gezien de supra normale longfunctiewaarden. In 
deze specifieke astmapopulatie ligt het belang van FENO voornamelijk in zijn hoge 
specificiteit. Toch een FENO waarde onder 34ppb zou de clinicus moeten overtuigen 
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een methacholine provocatietest aan te vragen om de diagnose alsnog te 
bevestigen.  
In het vijfde deel van deze thesis hebben we een nieuwe methode voorgesteld om 
astma te classificeren, gebaseerd op de compartimentalisatie van de eosinofiele 
inflammatie. Door gelijktijdig eosinofiel aantallen in bloed en sputum te bestuderen 
hebben we een subgroep van astmatici geïdentificeerd, die gekarakteriseerd wordt 
door een eosinofiele inflammatie, zowel systemisch als in de luchtwegen. 
Deze subgroep bestond voornamelijk uit mannen, had een slechtere astmacontrole, 
een slechtere longfunctie en was gevoeliger voor exacerbaties. Wat betreft de 
comorbiditeiten, had deze groep ook vaak neuspoliepen. 
We denken dat deze nieuwe classificatie nuttig kan zijn, daar er nu behandelingen 
bestaan die enerzijds gericht zijn op de eosinofiele luchtweginflammatie 
(inhalatiecorticosteroïden) of anderzijds op systemische eosinofiele inflammatie 
(orale corticosteroïden, anti-IL-5).  
 
Conclusie  
Het wordt steeds duidelijker dat de classificatie van astmapatiënten op basis van 
inflammatoire fenotypes zal bijdragen tot de keuze van behandeling. 
Geïnduceerd sputum is de gouden standaard als niet-invasieve methode voor 
inflammatoire fenotypering. We hebben aangetoond dat deze techniek als 
routineonderzoek kan gebruikt worden in een universitair centrum. 
We hebben ook een nieuwe classificatie van inflammatoire fenotypes voorgesteld, 
gebaseerd op bloed- en luchtwegeosinofilie, een classificatie die een subgroep van 
patiënten identificeerde met een diffuse eosinofiele inflammatie, slechte 
astmacontrole en hoger risico op exacerbaties.  
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Vermits we begrijpen dat de techniek van geïnduceerd sputum mogelijks nooit in de 
klinische praktijk zal worden toegepast in niet-universitaire centra, hebben we 
eveneens surrogaat merkers geïdentificeerd voor de identificatie van inflammatoire 
fenotypes. 
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Chapter 1. Introduction 
1.1   Definition of asthma 
Asthma is a heterogeneous disease of the airways resulting from a complex 
interaction between genetic and environmental factors. It is a chronic inflammatory 
disease of the airways in which various cells and mediators play a role (1). Type 2 
high asthma is characterised by increased cytokines following a TH2 pattern. The 
traditional guidelines for asthma diagnosis include suggestive clinical symptoms and 
the demonstration of airflow variability. However, symptoms and lung function are 
relatively insensitive in reflecting the underlying airway inflammation (2;3).  
1.2   Asthma management 
The aim of asthma management is to obtain asthma control and to reduce the risks 
of exacerbations (4). Treatment schemes follow a step-wise approach based on the 
level of severity and on the level of symptoms reported by asthmatics (5). All these 
parameters are subjective and involve patients’ perception. Monitoring of airway 
inflammation provides objective markers of assessment but requires time, as well as 
technical and financial resources. The importance of managing asthma on the basis 
of inflammatory biomarkers is highlighted in patients with discordance between 
symptoms and airway inflammation (6). Patients with discordance between 
symptoms and eosinophilic inflammation were the ones who benefited from 
inflammation-guided management (Fig 1). 
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1.3   Asthma inflammatory phenotypes 
As knowledge of airways disease has grown it has become apparent that asthma is 
not a simple, easily defined disease. Bronchial asthma is a complex disease of the 
airways with many different underlying mechanisms. It is now considered as a 
syndrome containing several subtypes with similarities and differences caused by 
variable underlying aetiologies (7). In the past, treatment options for asthma were 
limited; hence the need to define subtypes was not present. According to GINA 
guidelines, asthma treatment must be adjusted according to asthma control, rescue 
medication consumption, lung function and the risk of exacerbations. However, the 
relationship between airway inflammation and asthma symptoms or lung function is 
uncertain. As treatment options have grown so has our need to predict who will best 
respond to therapies, and optimise quality of life by reducing the risk of future events 
(such as exacerbations) that impair it. There is a need to focus on asthma subtypes 
by detailed clinical characterisation or differences in pathobiology. These subtypes 
are commonly called ‘phenotypes’. Progression in asthma is known to be much more 
complex than deterioration in lung function alone and harder to compare effectively 
between subtypes. The inherent variability of asthma also complicates the 
assessment of overall prognosis. Several phenotypes described in the literature are 
based on clinical features found in asthmatics databases and cluster analyses. 
Molecular and genetic approaches have also been widely used to categorise patients 
(8). This merging of clinical and pathophysiological features has been reviewed 
extensively elsewhere (9), often using the word endotype to delineate this way of 
defining disease.  
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1.3.1 Clinical interest of phenotyping 
Studies based on factor analysis tell us that airway inflammation is an independent 
domain of the asthma syndrome, distinct from airways hyperresponsiveness, 
abnormal lung function and respiratory symptoms (2;6). Common maintenance 
treatments of asthma such as anti-leukotrienes or inhaled corticosteroids and new 
biotherapies are directed towards modifying the underlying inflammatory process 
rather than improving symptoms.  An example was given by the studies on treatment 
targeting IL-5, a very specific pathway in asthma. This treatment did not significantly 
improve an unselected population of severe asthmatics while it improved asthma 
control and reduced exacerbation in selected patients exhibiting eosinophilic 
phenotype despite a treatment with high doses of inhaled corticosteroids, in which IL-
5 pathway is important (10;11).   
 
 
Fig 1. Cluster analysis to identify clinical phenotypes of asthma in primary- and 
secondary-care asthma populations. Although reasons for this dissociation between 
symptoms and eosinophilic inflammation are unclear, the use of measures of airway 
inflammation in these subgroups is clinically informative (Reprinted with permission of 
the American Thoracic Society. Copyright © 2014 American Thoracic Society. Haldar et 
al., 2008, Am J Respir Crit Care Med Vol 178. pp 218–224. Official Journal of the 
American Thoracic Society (6)).  
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1.3.2 Inflammatory pathways 
Based on sputum cell analysis, four inflammatory phenotypes have been described in 
the literature: eosinophilic, neutrophilic, paucigranulocytic and mixed granulocytic 
phenotype. The importance of these inflammatory phenotypes is that the underlying 
molecular mechanisms are different. While the eosinophilic phenotype is likely to 
reflect ongoing adaptive immunity in response to allergen with Th2 cytokine IL-4, IL-5 
and IL-13 playing a key role, the neutrophilic is thought to reflect innate immune 
system activation in response to pollutants or infectious agents (9;12) (Fig 2). 
Therefore it is conceivable that the two phenotypes actually require different 
therapeutic molecular approaches.  
 
Fig 2. Acquired and innate immune pathways leading to IL-5 mediated eosinophil 
inflammation (acquired pathway) or IL-8 mediated neutrophil inflammation (innate pathway). 
Adapted from Douwes et al.Thorax 2002. 
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1.3.3 Targeted therapy 
Phenotyping asthma according to airway inflammation can thus allow the 
identification of subgroups of patients who are more likely to respond to targeted 
therapy.  
 
1.3.3.1 Eosinophilic phenotype 
In particular, important studies have confirmed that eosinophilic airway inflammation 
most reliably predicts the response to anti-inflammatory treatment such as inhaled 
corticosteroids (13;14) and anti-IL5 (15;16). Numerous studies showed that regular 
treatments with ICS sharply and quickly reduce the percentage of eosinophils 
contained in the sputum from asthmatics (17;18), repress the release of Th2 
cytokines from lymphocytes (19), and eotaxin from epithelial cells (20). ICS are 
particularly effective in combating Th2-driven inflammation featuring mast cell and 
eosinophilic airway infiltration. Their effect on innate immunity-driven neutrophilic 
inflammation is rather poor.  
Several studies have demonstrated the usefulness of induced sputum to guide 
asthma treatment (21;22). These studies showed that targeting the sputum 
eosinophil count <2-3% for adjustment in the dose of ICS in moderate to severe 
asthma results in a marked reduction in asthma exacerbations and hospitalisations. 
This reduction of exacerbations was obtained without an increase in total dose of 
inhaled corticosteroids. Sputum eosinophil count follow-up has allowed selecting 
patients requiring high doses of inhaled corticosteroids and those with non-
eosinophilic asthma in whom corticosteroid doses have been decreased without 
worsening of asthma control (21). Another study including patients with refractory 
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eosinophilic asthma (sputum eosinophil count >2%) has shown that triamcinolone 
intramuscular administration was able to abolish sputum eosinophilic inflammation. 
This suggests that patients in whom asthma remains uncontrolled despite high-dose 
inhaled corticosteroids may be improved by systemic corticosteroid administration 
(23). This important study points to a reduced sensitivity rather than to a real 
resistance of eosinophilic inflammation to corticosteroids. 
1.3.3.2 Non-eosinophilic phenotypes 
There is no evidence that inhaled corticosteroids may improve short-term asthma 
control in the absence of uncontrolled eosinophilic inflammation as encountered in 
pauci-granulocytic asthma (14;24). On the other hand data suggest that severe 
neutrophilic asthma could be best targeted by using clarithromycin (25;26). In 
neutrophilic asthma, absolute value and percentages of sputum neutrophils have 
been associated with altered FEV1 suggesting that neutrophilic inflammation could 
play a role in lung function decline in asthmatics (27;28). Anti-inflammatory properties 
of macrolides include a decrease in IL-8 and a reduction in neutrophils recruitment 
and activation.  
Characterising the inflammatory phenotype in patients with chronic respiratory 
symptoms can thus be more important than giving an “asthma” label to predict 
response to anti-inflammatory treatment.  
1.3.4 Prediction of the risk of exacerbations and lung function decline 
Induced sputum analysis can allow the clinician to use inflammatory cell 
characteristics to interpret the aetiology of a patient’s symptoms and to predict the 
risk of exacerbations and prognosis. It has been shown that induced sputum was 
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able to detect an increase in eosinophilic inflammation after allergen challenge in 
sensitised asthmatics (29;30). Exacerbations are indeed associated with increased 
eosinophilic inflammation in case of intense allergen exposure (31) or with increased 
neutrophilic inflammation in case of infectious aetiology (32). A prospective study has 
found a correlation between sputum eosinophils percentage and FEV1 decline after 5 
years (33) suggesting a prognostic value of sputum eosinophil count in asthma 
follow-up. Jatakanon has shown that the percentage of sputum eosinophils was a 
predicting factor of loss of asthma control (34) when stepping down ICS. In another 
study, Leuppi reported that sputum eosinophil percentage >6.3% was a predictor of 
loss of asthma control after inhaled corticosteroid cessation with 90% sensitivity and 
63% specificity (35). Persistent airway eosinophilic inflammation despite intensive 
anti-inflammatory treatment has been associated with more severe asthma (36;37), 
more frequent exacerbations (21) and accelerated lung function decline (38). The 
association of increased eosinophilic and neutrophilic inflammation (mixed 
granulocytic asthma) is often associated with more severe disease (39;40). 
Neutrophils seem to play a role in airway calibre while eosinophils are associated 
with bronchial hyperresponsiveness (27;41). It has been shown that sputum 
eosinophil count increases several weeks before exacerbation (34;42) so a treatment 
strategy based on airway inflammation seems to be appropriate to prevent 
exacerbations (21;34). 
1.3.5 Distribution of inflammatory phenotypes 
Gibson et al. found that 41% of non-smoking asthmatics had a sputum eosinophil 
count >2.5% (43). Simpson et al. showed in a population of 93 asthmatics that 41% 
had eosinophilic asthma (>1%), 20% neutrophilic asthma (>61%), 31% 
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paucigranulocytic asthma and 8% mixed granulocytic asthma. The proportion of 
eosinophilic asthma reported by Louis (44) and Green (13) was higher (69% and 
52% respectively) but the thresholds used in those studies were 2 and 1.9% 
respectively and patients recruited in the former study were essentially mild 
corticosteroid-naïve atopic asthmatics. A recent American multicentre study found 
that paucigranulocytic asthma accounted for more than 50% of patients while 
eosinophilic asthma (≥2%) represented roughly 25%. In this study, neutrophilic 
phenotype and mixed granulocytic asthma represented less than 15% and 5% 
respectively.  
1.3.6 Biomarkers available to classify asthmatics in inflammatory phenotypes 
1.3.6.1 Induced sputum 
Currently available data seem to underline the robustness of induced sputum as a 
non-invasive method of collection of airway cells and lining fluid for assessing airway 
inflammation in asthma to identify inflammatory phenotype. Since its first description 
as a diagnostic tool for Pneumocystis carinii in AIDS patients (45), the technique has 
been used in chronic respiratory disease research and to monitor airway 
inflammation in clinical practice (46). It is however technically demanding and time 
consuming. There is a need for surrogate markers to identify neutrophilic and 
eosinophilic phenotypes to allow for personalised medicine. A biomarker is a 
surrogate measurement designed to characterise and quantify an underlying disease 
process (47). The use of biomarkers in exhaled air has the potential to unravel 
disease heterogeneity (48).  
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1.3.6.2 Surrogate markers for eosinophilic phenotype 
1.3.6.2.1 Exhaled nitric oxide 
The role of exhaled nitric oxide (FENO) as a valid marker of airway eosinophilic 
inflammation has been debated. Online measurement of FENO has the advantage of 
being simple and providing immediate results. Some studies (49-53), have shown a 
correlation between FENO and eosinophil in both mucosal biopsies and induced 
sputum. Berry et al. found that a FENO value ≥8.3 ppb in non-smokers predicted a 
sputum eosinophil count >3% when measured at a flow rate of 250 ml/s(49). The 
importance of correlations between FENO and induced sputum eosinophil counts 
varies widely in the literature and the clinical utility of FENO remains doubtful (54;55) 
as FENO was shown to be less successful than induced sputum (21;22) in guiding 
therapy in asthma management.  
1.3.6.2.2 Systemic biomarkers  
It is unclear whether systemic inflammation is able to predict airway inflammatory 
phenotypes. This alternative test is biologically plausible since the infiltrating 
granulocytes in the airway are bone marrow-derived cells, which access the airway 
through diapedesis from the circulation. The appeal of the approach comes from the 
ease of sample collection of peripheral blood from subjects of all ages and clinical 
characteristics.  
1.3.6.2.3 Other exhaled biomarkers 
Nitric oxide measure in exhaled air may not be the only diagnostically relevant 
molecule in exhaled breath. Breath VOCs might originate from either inside or 
outside the body, as endogenous products of metabolism or from exogenous sources 
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such as air, food and water. Volatile organic compounds (VOCs) present in the 
exhaled air were shown to be able to discriminate between various lung pathologies 
(56;57). Several studies have already suggested the usefulness of VOCs detection in 
exhaled air as a diagnostic tool in brain, prostate and lung cancer as well as in 
tuberculosis, asthma and COPD.  Electronic nose (eNose) has been shown to be 
able to discriminate between asthma and controls with similar accuracy to FENO and 
sputum eosinophils (58). However, eNose identifies a breathprint pattern associated 
with a disease without precise identification of the compounds present in the exhaled 
air.  
We sought to determine the ability of VOCs to discriminate between 
paucigranulocytic asthma and eosinophilic asthma. Moreover, non-invasive 
assessment of breath metabolites offers the potential for providing insight into 
inflammatory pathways. Inflammation-associated oxidative stress leads to 
peroxidation of polyunsaturated fatty acids thereby generating volatile organic 
compounds (VOCs) excreted in exhaled air. We hypothesised that inflamed lungs 
secrete different patterns of VOCs than normal healthy lungs. Asthma is 
characterised by specific biomarkers that reflect an altered airway redox chemistry, 
including lower levels of pH, and increased reactive oxygen species (ROS) (59) and 
reactive nitrogen species (RNS) (60). A potential source for the generation of 
microbicidal and pathological levels of superoxide anion (O2•-) is the NADPH 
oxidase, which is found in neutrophils, eosinophils, monocytes, and macrophages. 
Most of the O2•- generated in vivo undergoes a nonenzymatic or superoxide 
dismutase (SOD-) catalysed reaction resulting in its dismutation into hydrogen 
peroxide (H2O2). Once formed, the oxidising potential of H2O2 may be amplified by 
eosinophil- and neutrophil-derived peroxidases, EPO and MPO, respectively. Recent 
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evidence supports the key roles of endogenous NO and NO-derived reactive nitrogen 
species (RNS) in modulating airway function and inducing asthma (60). Previous 
studies have shown that some NO metabolic by-products exhibit cytotoxic effects in 
the central and peripheral bronchioles and alveoli. For instance, the rapid reaction 
between superoxide and NO produces a highly unstable RNS, peroxynitrite 
(ONOO−), which has been involved in cellular damage and airway hyper-
responsiveness (61). Highly bioactive NO and NO-derived RNS can inflame the 
airways and could be measured in exhaled air. The oxidative and nitrosative stresses 
can be elicited by allergens and irritants (62).  
Because the field of breath analysis is relatively new and the advances in analytic 
technology occur so fast, many compounds in exhaled breath have been detected by 
gas chromatography and mass spectometry. Analysis of exhaled breath for 
recognition of asthma phenotype using endogenous volatile organic compounds 
offers the possibility of noninvasive diagnosis and therapeutic monitoring. Several 
studies have shown that eNose was able to discriminate between various diseases 
(63-68). However eNose cannot identify individual VOCs. To unravel which VOCs 
drive the distinctive patterns between different asthma phenotype, specific analysis of 
individual compounds with GC-MS is necessary.  
1.3.6.3 Surrogate markers for neutrophilic phenotype 
We currently lack of marker predicting airway neutrophilic inflammation. There is 
evidence that non-eosinophilic asthma is not improved by treatment with inhaled 
corticosteroids (14;24) while macrolides were shown to decrease the number of 
exacerbations in severe non-eosinophilic asthma (25;26). Analysis of exhaled air 
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using chromatography and mass spectrometry could allow identification of breath 
prints specific to neutrophilic phenotype.  
1.4 Exhaled nitric oxide and airway hyperresponsiveness 
Some early studies suggested that high FENO might reflect the presence of bronchial 
hyperresponsiveness (69). As FENO was identified as a surrogate marker for 
eosinophilic phenotype, we wondered if FENO was also a marker of airway 
hyperresponsiveness. Some studies have suggested FENO may be helpful in 
diagnosing asthma but it remains debated (69;70). Both sputum eosinophil count and 
FENO have been proposed as a useful diagnostic tool (71) in mild to moderate 
asthma. In this group of patients airway inflammatory markers proved to be superior 
to classic FEV1 reversibility to β2-agonist or to peak expiratory flow (PEF) variability 
criteria but slightly less efficient than methacholine challenge (70;71). Asthma 
diagnosis remains a challenge in clinical practice (72) and either reversibility test or 
bronchial provocation challenge is required to confirm the diagnosis according to 
GINA guidelines (5). There is a need for a simple, quick and reliable test in those 
patients with symptoms suggestive of asthma. Early studies have suggested that 
fractional exhaled nitric oxide, measured with a cut-off of 16ppb at a flow rate of 
200ml⁄s may help to identify patients with bronchial hyperresponsiveness to 
histamine or reversibility to β2-agonist among those presenting with chronic 
respiratory symptoms and normal baseline lung function (specificity of 90% and PPV 
>90%) (73). FENO alone is not a diagnostic test for asthma as elevated levels of 
FENO have been found in other pathologies such as eosinophilic bronchitis (74), 
allergic rhinitis and COPD (75). Moreover, factor analysis has revealed that airway 
inflammation and bronchial hyperresponsiveness towards methacholine load in 
different clusters in patients with long disease duration (2;76). On the other hand, 
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FENO has been shown to correlate with new-onset wheeze in a longitudinal 
population study (77). Airway hyperresponsiveness assessed by methacholine 
challenge is time consuming and unpleasant to the patient whereas FENO 
measurement is easy to perform and provides immediate results. In patients 
exhibiting unspecific respiratory symptoms, a low level of FENO could suggest 
alternative diagnosis and the absence of response to anti-inflammatory treatment.  
 
1.5 Clinical implications of the site of eosinophilic inflammation in asthma 
The eosinophilic feature is recognised as a pivotal trait of bronchial asthma (36). 
However, there are patients who show discordance between local and systemic 
inflammation. There is a huge controversy about the role of eosinophils as a key 
player in asthma severity (34;40;50;78-86). Some studies have looked at airway 
eosinophils in bronchoalveolar lavage (BAL) (86), induced sputum (34;79;80;82;83) 
and bronchial biopsies (84;85), while others focused on systemic inflammation 
through blood eosinophil count measurement (85). Discrepancies between studies 
may be linked to the different compartments sampled and, for some of the studies, to 
the limited number of subjects investigated. While inhaled corticoids, the 
recommended mainstay treatment of asthma, have been consistently shown to 
reduce airway eosinophilic inflammation and improve asthma control (87), their effect 
on systemic eosinophilia was shown to be rather weak at usual doses (88). By 
contrast, the new biologicals directed towards interleukin-5 were shown to 
dramatically decrease circulating blood eosinophils, an effect that was associated 
with the reduction of asthma exacerbation (11) and improvement in asthma control 
(10). To the best of our knowledge, there has never been detailed investigation of the 
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relationship between blood and sputum eosinophil in a large population of 
asthmatics.  
1.6 Severe asthma phenotype 
1.6.1 Severe asthma definition 
It is recognised that the majority of asthmatics may be controlled by regular treatment 
with ICS/LABA. Yet a small fraction of asthmatics called refractory or severe 
asthmatics escape this treatment (89;90). Severe asthma accounts for a major part of 
the financial burden asthma poses to the health care system (91). This phenotype is 
defined by inadequate asthma control or frequent severe exacerbations despite high-
dose inhaled corticosteroids or the need for oral corticosteroids often associated with 
other controller medication such as long-acting β2 agonists, leukotriene receptor 
antagonists or theophylline (92;93). Refractory asthmatics are patients in whom 
alternative diagnoses have been excluded, co-morbidities have been treated, trigger 
factors have been removed and adherence with treatment has been checked. By 
itself this phenotype clearly points out the inability of corticosteroids to control 
disease expression in some asthmatics. A functional variant of glucocorticosteroid 
transcript 1 gene (GLCCl1) was found to be associated with decreased response to 
ICS in several randomised clinical trials (94). Reduced eosinophil apoptosis in 
induced sputum despite a high dose of ICS was shown to be related to disease 
severity (95). 
1.6.2 Severe asthma management 
While evaluation and monitoring of airway inflammation does not seem to be 
warranted in everyday clinical management of controlled mild-to-moderate asthma, 
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the assessment of the inflammatory phenotype is required in severe asthma that is 
resistant to conventional treatment and may help to reduce exacerbation rates. The 
recent ERS/ATS guidelines suggest that induced sputum can be used in the 
management of severe asthma in specialised centres with a dedicated laboratory 
(93).  
1.6.3 Severe asthma inflammatory subphenotypes 
Severe asthma is not a single disease itself but can be divided into several 
subphenotypes according to inflammatory, clinical and functional characteristics (96). 
Those phenotypes may have prognostic value and therapeutic implications. 
However, severe asthma subphenotypes have not yet been fully characterised. Early 
reports suggested that patients with more severe asthma had increased eosinophil 
(40) or neutrophil (39) counts in induced sputum and in bronchial biopsies (97).  
1.6.4 Targeted therapies available for severe asthma 
Most of the new biological treatments available for severe asthma are monoclonal 
antibodies directed against specific immunologic processes and in particular against 
cytokines. Several cytokines are involved in the pathophysiology of asthma including 
Th2 cytokines. It is critical to assess inflammation in severe asthma to predict the 
response to targeted therapies.  
In those refractory asthmatics with moderately elevated total serum IgE and 
sensitisation to a perennial allergen, omalizumab, a humanised monoclonal antibody 
against IgE has proved to be effective in reducing exacerbation rate and improving 
quality of life (98;99) although part of the effect in quality of life improvement seen in 
clinical practice is likely to be due to a placebo effect and a careful follow-up of the 
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patient inherent in the mode of drug administration (100). The importance of IL-5 in 
driving the persistent systemic and airway eosinophilic inflammation has been 
demonstrated by the efficacy of mepolizumab, an anti-IL-5 monoclonal antibody, to 
further decrease eosinophilic inflammation in those patients with refractory asthma 
despite high dose of corticosteroids (15;16). The clinical relevance of the persistent 
eosinophilic inflammation is demonstrated by the reduction in exacerbation rate and 
the improvement in quality of life observed in those patients receiving mepolizumab, 
even if no effect is observed on airway calibre and bronchial hyperresponsiveness 
(15). IL-13 is increased in severe asthma and causes corticosteroid resistance so is a 
logical target. Anti-IL-13 such as lebrikizumab has been disappointing with little 
physiological effect and no effect on symptoms or exacerbations (101). A recent 
study with anti-IL-17 has shown no effect on ACQ score, FEV1 and symptom-free 
days (102).   
Anti-TSLP, which was found effective in the model of acute bronchial allergen 
challenge, still has to prove its validity in improving asthma control and reducing 
asthma exacerbation. It is indeed worth noting that anti-IL5 whose effect on asthma 
control and exacerbation in severe eosinophilic asthma has been recently 
established, was shown to fail in protecting against acute and late bronchospasm 
after allergenic challenge.  Blocking antibodies to other cytokines including IL-9, IL-25 
or IL-33 are also in development for asthma. The major drawback of such treatments 
is the high cost which weakens the cost-effectiveness relationship.  
The studies focusing on neutrophilic inflammation in refractory asthma have been 
limited so far. Studies using clarithromycin or azithromycin have shown a significant 
reduction of sputum neutrophil count together with improved quality of life and 
decreased severe exacerbation rate in non-eosinophilic severe asthmatics (25;26). 
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Long-lasting studies on larger asthma cohorts are warranted before claiming 
macrolides may be used as maintenance treatment in severe neutrophilic or at least 
non-eosinophilic asthma. 
Bronchial thermoplasty is an innovative non-pharmacological treatment approach to 
reduce the bronchoconstrictor response in asthma (103). During this bronchoscopic 
procedure, all visible and reachable airways are treated with radiofrequency energy 
provided by the Alair catheter (Asthmatx, Inc., Mountain View, CA, USA) introduced 
via a flexible bronchoscope in order to reduce airway smooth muscle mass (104) and 
decrease bronchial reactivity. It has been shown to improve asthma control and 
quality of life and to be safe in moderate to severe asthmatics (105;106).  
1.6.5 Severe asthma registries 
Studying large numbers of severe asthmatics recruited in daily practice is critical to 
better understand and treat severe asthma. Several severe asthma cohorts and 
registries aimed to collect data and information on severe asthma in Europe and 
USA. The European Network for Understanding Mechanisms of Severe Asthma 
(ENFUMOSA) (107), the BIOAIR European study (108), the TENOR (109) and the 
SARP study (110) and the UK multicentre registry on refractory asthma (111) have 
yielded recent insights into the demographics, and functional and inflammatory 
features of asthma. This information helps guide effective management of patients 
with severe asthma by improved understanding of factors associated with poor 
asthma control and high levels of healthcare resource use.   
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2 Chapter 2. Aim of the thesis 
2.1 Description of inflammatory phenotypes 
The aim of the present thesis was first to look at the distribution of inflammatory 
profiles based on induced sputum. We wanted to describe the distribution of 
inflammatory phenotypes in a large asthmatic population encompassing the whole 
disease severity spectrum and in a population of severe asthmatics recruited from 9 
Belgian academic centres in the Belgian Severe Asthma Registry. We also looked at 
the demographic, functional and inflammatory characteristics of the different 
inflammatory phenotypes. 
2.2 Value of FENO measurement in clinical practice 
Exhaled nitric oxide is an easily applicable and widely available measurement. We 
wanted to highlight the link between this biomarker and eosinophilic inflammation, 
bronchial hyperresponsiveness and respiratory symptoms. As we thought that the 
doubt on the utility of FENO to identify eosinophilic phenotype was due to the use of 
inappropriate cut-off points, we further searched for series of predictive cut-off points 
taking into account factors that were found to influence FENO levels.  
2.3 Factors associated with eosinophilic and neutrophilic inflammation 
We wondered whether patients with eosinophilic versus neutrophilic inflammation 
may be distinguished by demographic, functional and immunologic features. As 
induced sputum is a complex and expensive technique, we wanted to identify 
surrogate markers for airway inflammation. We wanted to test the ability of volatile 
organic compounds in differentiating between asthma inflammatory phenotypes.  
 
50 
 
2.4 Clinical interest of a new asthma classification based on compartmental 
eosinophilic inflammation 
As there are patients exhibiting discordance between local and systemic 
inflammation, we wanted to study the added value of measuring blood and sputum 
eosinophil cell counts. We wondered whether patients’ characteristics varied 
according to the amount and site of eosinophilic inflammation. 
2.5 Setting up the severe asthma registry in Belgium 
The Belgian Severe Asthma Registry (SAR) is a national Belgian secured web 
database for severe asthma initiated by the Asthma Working Group of the Belgian 
Thoracic Society. We wanted to collect epidemiological and clinical data from the 
Belgian Severe Asthma population in order to raise awareness of severe asthma, to 
identify several phenotypes, to promote optimal care for these patients and to be a 
valuable platform of patients for new severe asthma drug testing. We also sought to 
compare the findings to that of ENFUMOSA(107) and BIOAIR European study(108), 
the TENOR study (109), the SARP study (110) and the UK multicentre registry on 
refractory asthma (111).   
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3 Chapter 3. Methods 
3.1 Subject characteristics and study design  
Patients with asthma were recruited from the University Asthma Clinic of CHU Liege 
between October 2005 and January 2014 while severe refractory asthmatics were 
recruited from 9 Belgian centres (CHU Liege, Ghent University Hospital, Mont-
Godinne, Erasme, Cliniques universitaires de Saint-Luc, CHU Vesale, CHU St Pierre, 
Brugman and UZ Leuven) between March 2009 and January 2014.  
3.2 Visit to the asthma clinic of CHU Liege 
Patients attended the clinic on two days at an interval of one week. On day 1, each 
patient underwent FENO measurement at a flow rate of 50 ml/s followed by 
spirometry with bronchodilation, sputum induction, blood sampling and validated 
asthma control and quality of life questionnaires. All tests were performed on the 
same day. On day 2 the subjects underwent methacholine challenge after refraining 
from using bronchodilators for the appropriate time (8h for short-acting 
bronchodilators and 24h for long-acting bronchodilators) as long as the baseline 
forced expiratory volume in 1s (FEV1) value was not less than 70% predicted. 
Asthma was diagnosed based on the presence of chronic respiratory symptoms such 
as cough, breathlessness or dyspnea together with the demonstration of airflow 
variability. The latter was defined by airway hyper-responsiveness shown by one or 
more of the following: increase in Forced expiratory volume in 1 s (FEV1) of >12% 
and 200 ml following inhalation of 400 μg salbutamol or inhaled concentration of 
methacholine provoking a 20% fall in FEV1 of <16mg/ml. Methacholine challenge was 
performed according to a standardised methodology as previously described (44). 
Subjects were characterised as atopic if they had at least one positive specific IgE 
52 
 
(>0.35 kU/l; Phadia) for at least one common aeroallergen (cat, dog, house dust 
mites, grass pollen, tree pollen and a mixture of moulds). Quality of life was assessed 
using the self-administered Asthma Quality of Life Questionnaire (AQLQ) (112) and 
asthma control by the Juniper Asthma Control Questionnaire (ACQ) (113) and 
Asthma control test (ACT) (114).  
Our studies were conducted with the approval of the ethics committee of CHU Liege. 
3.3 Investigation of bronchial inflammation 
As bronchial endoscopy is an invasive technique, inflammatory cell count on 
bronchial biopsies and bronchoalveolar lavage are not widely used to assess 
inflammation in asthmatics. Several non-invasive techniques have been developed to 
evaluate airway inflammation. Induced sputum has been shown to be able to reflect 
airway inflammation and its evolution. 
3.3.1 Sputum induction 
Sputum was induced and processed as previously reported (115). The patients 
received inhaled salbutamol 400µg administered through pMDI and Volumatic (Glaxo 
Smith Kline, UK) 20 minutes before sputum induction. Saline was inhaled through an 
ultrasonic nebuliser (Devilbiss 2000), the mean output of which was calculated to be 
0.93 ml/min. The cup of the nebuliser was filled with 50 ml hypertonic or isotonic (if 
FEV1 value was less than 65% predicted (116)) saline to which was added 1.75 ml 
salbutamol solution at 5 mg/ml. FEV1 was measured at 5, 10, 15 and 20minutes after 
starting inhalation or earlier in case of worsening respiratory symptoms. Inhalation of 
saline was stopped after 20 minutes or when a fall in FEV1 of 20% from baseline had 
occurred. After performing spirometric measurements at 5, 10, 15 and 20 minutes the 
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subjects were asked to rinse their mouth with tap water and to cough up sputum into 
a plastic container. For safety reasons, FEV1 was measured 10 minutes after the end 
of the induction in every patient. Sputum should be processed within two hours in 
order to ensure optimum cell counting and staining. For sputum processing, samples 
were poured into a 50ml polypropylene tube, weighed, and diluted with a threefold 
weight of a phosphate buffered saline (PBS) solution for homogenisation. The 
samples were then rocked at room temperature for 20 minutes and centrifuged at 
400g for 10 minutes at 4°C. The supernatant was stored at –80°C until biochemical 
analyses for albumin and histamine. The cellular phase was dispersed in 1 ml PBS 
without Ca2+ and Mg2+ solution for total cell counts using a manual 
haemocytometer. The differential cell count was performed on cytospins stained with 
Diff-Quick by counting 500 cells under a light microscope (Dade, Brussels, Belgium). 
Cellular viability was evaluated using trypan blue. 
Sputum induction was successful in 78% of the patients encountered in our asthma 
clinic which is similar to previous reports (95;117). As the technique is non-invasive, it 
has been applied to a large series of healthy subjects in order to derive reference 
values. A series of 113 healthy subjects including 24 current smokers was sampled in 
University of Liege hospital (118). There are three other detailed published studies 
that investigated the sputum cell counts in large numbers of non-smoking healthy 
subjects (119-121). When deriving the upper limit of the 90% reference interval 
(mean +1.7SD), abnormally high neutrophil count ranges from 49% according to 
Spanavello (120) to 93% according to Thomas (121), most of the authors setting the 
threshold between 61% and 76%. It is recognised that the number of neutrophils is 
influenced by age and may rise rapidly in the sputum as a consequence of airways 
irritation (122) or exposure to pollutants (123). This could explain the variability of 
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normal range according to the studies conducted in different countries. In our 
experience, an abnormally high sputum neutrophil count is defined as a percentage 
≥76% calculated as mean + 1.7 SD (mean±SD: 34.9+/-24.3%; n=113) (118). 
As opposed to what has been found for neutrophils, there is much less variation 
according to the centres with respect to the eosinophil percentage. The abnormal 
threshold ranges from 1% according to Simpson (124) to 2.6% according to our 
reference values (118). To give a safe margin in the cell counting, it has been 
accepted that an abnormal sputum eosinophil count is ≥3%. 
In our studies, eosinophilic phenotype was defined as ≥3% sputum eosinophil count 
while neutrophilic phenotype consisted of ≥76% sputum neutrophil counts (118).  
It has been shown that early sputum (after 5 minutes) contains more granulocytes but 
less mononuclear cells than late sputum (after 20 minutes). 
As compared to bronchoalveolar lavage, induced sputum in healthy subjects displays 
more neutrophils and less lymphocytes and macrophages (125-127). Induced 
sputum is more indicative of proximal inflammation but sputum eosinophil count has 
been shown to be well correlated to distal eosinophil count in bronchoalveolar 
lavage. Comparison of bronchial biopsies and sputum in the same subject showed 
that sputum eosinophils reflect airway wall eosinophil content while this did not hold 
true for the neutrophils (125;127). The latter are present in greater number in airway 
lumen, and therefore in sputum, than in airway walls.  
3.3.2 Exhaled nitric oxide 
The technique of induced sputum is complex and time consuming. Moreover, in our 
experience, only 80% of asthmatics are able to cough up sputum (128). FENO has 
been considered as a good surrogate marker for sputum eosinophil count (49). 
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NO is mainly produced by epithelial cells in asthma but can also be released by mast 
cells, macrophages, endothelial cells and vascular smooth muscle cells. The 
synthesis of NO is mediated by constitutive (eNOS or nNOS) and inducible NO 
synthase. The production is due to oxidation of L-arginin to L-citrullin. iNOS is the 
only isoform correlated with exhaled nitric oxide (129). 
FENO is measured by chemoluminescence using a nitric oxide monitor set at an 
exhalation flow rate of 50ml/s according to the ERS/ATS recommendations (NIOX, 
Aerocrine, Sweden). Nitric oxide reacts with ozone to form hydrogen dioxide with 
photon emission that can be detected. The signal is proportional to the concentration 
of nitric oxide. NO concentration is inversely related to expiration flow. Nitric oxide 
measurement is precise, reproducible and gives immediate results. Nitric oxide is 
measured in part per billion (ppb). 
FENO has been shown to be correlated with blood eosinophils (130), sputum 
eosinophils (49), eosinophil counts in bronchial mucosa (131) and bronchoalveolar 
lavage (73). Adult asthmatics exhibiting FENO levels lower than 25ppb have a high 
probability of non-eosinophilic asthma (51;132) while patients with FENO levels 
>47ppb show a good response to inhaled corticosteroids.  
It is however highly likely that FENO and induced sputum are different facets of 
bronchial inflammation. Jatakanon has indeed shown that the change in sputum 
eosinophil count was better than the change in FENO in predicting loss of asthma 
control (34). Michils et al. have also shown that as opposed to induced sputum, it is 
more the individual change in FENO value than the absolute value of FENO that is 
predictive of asthma control. In this study, a reduction of FENO of 40% predicted 
improvement of asthma control with a PPV of 83% and a NPV of 79%. As opposed to 
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what is seen in studies evaluating sputum eosinophil count, FENO levels did not 
differ between mild to moderate asthma and severe refractory asthma (110). 
Indeed it has been shown that in the absence of elevated eosinophil count, FENO 
was highly predictive of a response to inhaled corticosteroids with a cut-off value of 
33 ppb (133). This could be due to eosinophils phagocytosis by macrophages whose 
presence could become undetectable in induced sputum but still reflected by FENO 
measurement (134).  
3.3.3 VOCs sample collection and analysis 
Exhaled air was sampled from patients in whom asthma had been diagnosed 
according to GINA guidelines and who were classified in asthma inflammatory 
phenotypes according to the results of sputum inflammatory cell count. Induced 
sputum was sampled on the same day as VOCs measurement. The recruitment of 
asthmatics stopped when eosinophilic, paucigranulocytic and neutrophilic 
phenotypes reached at least 50 asthmatics in each group. The mixed granulocytic 
asthmatics were quite rare so we decided not to include them in the statistical 
analysis.  
All breath samples were donated between 9 and 11a.m. in the same room, to 
minimise the effect of variation in background air. Exhaled air was collected by 
exhaling into inert Tedlar bags (5L). Subjects were asked to inhale, hold their breath 
for 5 seconds and subsequently fully exhale into the Tedlar bag. All Tedlar bags were 
washed twice with high-grade nitrogen as described by the manufacturer before 
usage to make sure all contaminants were eliminated. The content of the Tedlar bag 
was transported under standardised conditions onto desorption tubes; stainless steel 
two-bed sorption tubes, filled with carbograph 1TD/Carbopack X. These desorption 
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tubes were placed inside the thermal desorption unit and quickly heated to 270°C in 
order to release all VOCs and transport the released VOCs onto the GC-capillary. 
The used desorption unit was highly suitable for repeated, quantitative and 
reproducible measurements. Ten percent of the sample was injected into the GC, the 
remaining 90% transported to another adsorption tube for storage and may be used 
for later reanalysis. Just before the sample enters the GC, it is trapped by a cold trap 
at 5 degrees Celsius in order to concentrate the sample. Next, VOCs were separated 
by capillary gas chromatography (column: RTX-5ms, 30m x 0.25mm 5% diphenyl, 
95% dimethylsiloxane, film thickness 1.0µm, Thermo Electron Trace GC Ultra, 
Thermo Electron Corporation, Waltham, USA). The temperature of the 
chromatograph was programmed as follows: 40°C during 5 minutes, then raised with 
10°C/min until a final maximum temperature of 270°C in the final step, this 
temperature was maintained for 5 min. Time-of-flight mass spectrometry was used to 
detect and identify components available in the samples. Electron ionisation mode 
was set at 70eV and the mass range m/z 35-350 was measured. Sample frequency 
of the mass spectrometer was set to 5Hz and analysis run time to 33 minutes. 
3.4 Statistical analysis 
The results were expressed as mean ± SD for continuous variables; median and 
interquartile ranges (IQR) were preferred for skewed distributions. For categorical 
variables, the number of observations and percentages were given in each category. 
Comparisons between different subgroups were performed with a Kruskal-Wallis test. 
The Spearman correlation coefficient was used to measure the association between 
clinical parameters. The receiver-operating characteristic (ROC) curve was 
constructed to determine cut-offs for variables in order to distinguish between various 
subgroups. Logistic regression analysis was used to assess the relationship between 
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binary outcomes and sets of covariates, individually or in combination. We 
established formula taking into account independent predictors to predict the 
probability of inflammatory subphenotypes. The validity of the equations was tested 
in independent populations. The agreement between predicted and observed value 
was tested by Cohen Kappa’s coefficient. Calculations were done using SAS version 
9.1 (SAS Institute, Cary, North Carolina, USA). The results were considered to be 
significant at the 5% critical level (p < 0.05).  
 
To identify volatile organic compounds from the exhaled air able to discriminate 
between three asthma inflammatory subtypes (paucigranulocytic, eosinophilic and 
neutrophilic asthma), we used conditional Inference Forests (CIFs) (135) to build an 
ensemble of conditional inference trees and to rank features based on the ability of 
components to predict asthma inflammatory subtype. The advantage of CIF 
framework is that the node variable selection and its posterior splitting are two 
separate steps. The CIFs do not show bias towards variables with many possible 
splits and are scale-independent due to association measure based on Strasser and 
Weber’s work (136).  Thus CIFs implemented in party and party-kit packages 
(137;138) had been shown to provide a superior performance compared to traditional 
classification and regression trees (CART) including the widely-used Random 
Forests by Breiman (139). Briefly, the aim of the CIFs in this study was to find the 
components with the strongest association to the inflammatory phenotype in each of 
the three tested scenarios including eosinophilic/neutrophilic, 
eosinophilic/paucigranulocytic and neutrophilic/paucigranulocytic. The association of 
a particular component to asthma inflammatory subtype via CIFs allowed to identify 
only components that are deemed to be associated to specific phenotype, but did not 
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provide enough information to form a robust classifier. In order to extract further 
information and to see the direction of each component impact on the asthma sub-
type, we had conducted Student’s t-test on the top ranked components from CIFs 
analysis. The original data consisted of 276 asthmatics and 3328 components with 
122 patients exhibiting eosinophilic asthma, 50 with neutrophilic asthma, 14 with 
mixed granulocytic asthma and 90 with paucigranulocytic asthma. In order to improve 
power and reduce dimensionality of the dataset, we had filtered out the components 
that had < 30 samples (i.e. the mixed granulocytic group was not analysed). After 
filtering the eosinophilic/neutrophilic subset contained 172 samples and 561 
components, the neutrophilic/paucigranulocytic subset contained 140 samples and 
429 components, and the eosinophilic/paucigranulocytic subset contained 212 
samples and 714 components. The parameters to build Conditional Inference Forests 
included cquad test statistic (teststat="quad"), multiple-testing correction via Monte 
Carlo resampling (testtype="MonteCarlo", nresample=9999), 65% of the dataset was 
used to build trees and the remaining one to calculate variable importance 
(fraction=0.65), the minimum criteria to continue splitting the tree node was set at p-
value ≤ 0.01 (mincriterion=0.99), a minimum of 30 samples in a node were required 
to execute split (minsplit=30), a total of 999 trees were built (ntree=999), all predictor 
variables/components had a chance to be assigned to a tree node (mtry=0), the CI 
trees could have unlimited number of levels (maxdepth=0). The variable importance 
was calculated using the default settings of the varimp function. The importance of 
the variable/component was measured via the standard decrease in MSE 
(“%IncMSE”) measure. The statistical significance of the components identified 
across two asthma subgroups was calculated with the Student’s t-test assuming 
different variances in two groups.  
60 
 
All the studies were conducted with the approval of the ethics committee of CHU 
Liege B70720096732, reference Liege 2009/161.  
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4 Chapter 4. Results 
4.1 Distribution of inflammatory phenotypes in asthma 
4.1.1 Distribution in a large asthmatic population encompassing the entire 
disease severity spectrum 
We sought to assess the proportion of asthmatic patients displaying eosinophilic vs 
neutrophilic vs paucigranulocytic phenotypes based on sputum cell analysis.  
508 subjects were recruited from the University Asthma Clinic of Liege between 1st 
October 2005 and 27th June 2011. Their demographic and functional characteristics 
are summarised in Table 1. All the asthmatics recruited had given a successful 
sputum induction. From those patients, 211 (41%) had eosinophilic inflammation 
(≥3% eosinophils), 80 (16%) neutrophilic inflammation (≥76% neutrophils), 14 (3%) 
mixed granulocytic and 203 (40%) paucigranulocytic (sputum eosinophil count <3% 
and sputum neutrophil count <76%) inflammation (Fig 3). The proportions of 
inflammatory subtypes were rather similar after exclusion of steroid-treated patients 
(Table 2).  
The proportion of asthmatics with raised sputum eosinophil counts was 44% in our 
series, similar to Gibson et al. (41%) (43). The proportion of eosinophilic asthma 
reported by Louis (44) and Green (13) was higher but with thresholds of 2% and 
1.9% respectively. Our results are similar to Simpson’s study conducted on 93 
subjects using thresholds of 1 and 61% for eosinophilic and neutrophilic inflammation 
respectively. This group found 41% eosinophilic asthma, 20% neutrophilic asthma, 
31% paucigranulocytic asthma and 8% mixed granulocytic asthma (124). The higher 
thresholds used in our study certainly explain on the one hand the lower proportion of 
mixed granulocytic and neutrophilic asthma and on the other hand, the higher 
proportion of paucigranulocytic asthma in our patients. The American multicentre 
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study from McGrath et al. showed that the dominant phenotype was 
paucigranulocytic asthma (>50% of patients) while eosinophilic asthma (sputum 
eosinophil count ≥2%) represented roughly 25%. As in our study, the neutrophilic 
phenotype (sputum neutrophil count >61%) was quite rare representing less than 
15% of the patients while the mixed granulocytic phenotype was less than 5% (140). 
 
 
 
Table 1. Demographic, functional and inflammatory characteristics for the whole 
population. 
Characteristics  
N. 508 
Gender (M/F) 201/307 
Age, yrs 52 (19-88) 
Height, cm 167 ± 9 
Weight, kg 74 ± 16 
Atopy (Y/N) 296/212 (58%) 
Current Smoker (n) (pack-yr) 
Ex-smokers (n) (pack-yr) 
101  (22 (0.5-60)) 
99    (15 (0.5-90)) 
FEV1, % predicted 84 ± 19 
Sputum eosinophils, % 2 (0-94) 
Sputum neutrophils, % 45 (0-100) 
ICS therapy  
     Steroid-naïve 
     Low-dose ICS 
     Moderate-dose ICS 
     High-dose ICS 
 
153 (30%) 
73 (15%) 
138 (27%)   
144 (28%)    
Data are presented as mean ± SD or median (range). FEV1: forced expiratory 
volume in 1s. ICS: inhaled corticosteroids. Low dose: ≤500µg/day 
beclomethasone; Moderate dose: 500-1000µg/day beclomethasone; High dose: 
>1000µg/day beclomethasone. 
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Fig 3. Proportion of various inflammatory phenotypes according to cellularity of 
induced sputum in a large cohort of asthmatics. 
 
 
Table  2. Proportion of asthma inflammatory phenotypes in steroid-naïve and steroid-treated 
patients 
 Paucigranulocytic 
phenotype 
Eosinophilic 
phenotype 
Neutrophilic 
phenotype 
Mixed 
granulocytic 
phenotype 
Steroid-naïve 
(n=153) 
65 (42.5%) 60 (39.2%) 25 (16.3%) 3 (2%) 
Steroid-treated 
(n=355) 
138 (38%) 151 (43%) 55 (15%) 11 (3%)* 
*p<0.05. 
4.1.2 Distribution of phenotypes in a population of severe refractory asthma  
Sputum was induced in 86 out of 111 severe asthmatics (SA) in CHU Liege with a 
success rate of 77%. By comparison, Ten Brincke et al. found a success rate in 
severe asthma of 74% (116). In severe asthma, eosinophilic phenotype (sputum 
Eos≥3%) was the predominant phenotype (55%) while neutrophilic (sputum 
Neu≥76%) and paucigranulocytic asthma were 22% and 17% respectively (Fig 4). 
40% 
41% 
16% 
3% 
Asthma inflammatory phenotypes 
Paucigranulocytic
Eosinophilic
Neutrophilic
Mixed granulocytic
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The raised airway granulocytic inflammation is a common finding in severe asthma 
(40). The median sputum eosinophil count was higher than that observed in the UK 
SA cohort (111). We found a lower proportion of paucigranulocytic asthma in the 
severe asthma population than the 40% observed in the general population of 
asthmatics (128). Eosinophilic asthma was more frequent in severe asthma (55% vs 
41%) and neutrophilic asthma followed the same trend (21% vs 16% in the general 
population of asthmatics). Duncan (95) has demonstrated that both reduced 
eosinophil apoptosis and increased sputum eosinophilia significantly correlate with 
asthma severity. Neutrophilic inflammation was found to be increased in severe 
asthma (39). It has been suggested that this could be due to a protection of 
neutrophils from apoptosis by corticosteroids. The mixed granulocytic asthma was 
two times more frequently encountered in severe asthmatics than in the general 
population of asthmatics. Eosinophilic asthma was more frequently encountered in 
late onset asthma in our registry data. This is in line with previous reports (141).  
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Fig 4. Distribution of sputum cellular phenotypes in severe asthma 
(n=88). Eosinophilic asthma (≥3% sputum eosinophils, <76% sputum 
neutrophils); Neutrophilic asthma (<3% sputum eosinophils, ≥76% 
sputum neutrophils); Paucigranulocytic asthma (<3% eosinophils and 
<76% neutrophils in induced sputum); Mixed granulocytic asthma (≥3% 
eosinophils and ≥76% neutrophils in induced sputum). 
 
  
21% 
55% 
18% 
6% 
Inflammatory phenotypes 
Paucigranulocytic
Eosinophilic
Neutrophilic
Mixed granulocytic
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4.2 Demographic, functional and inflammatory characteristics of asthma 
phenotypes based on sputum cell analysis 
The demographic, functional and inflammatory characteristics are summarised in 
Tables 3 and 4. Compared to the paucigranulocytic phenotype, eosinophilic, 
neutrophilic and mixed granulocytic phenotypes were characterised by a poorer lung 
function.  
The eosinophilic phenotype exhibited higher frequency of atopy, higher levels of IgE, 
higher bronchial hyperresponsiveness to methacholine, higher FENO levels and 
lower asthma control compared to paucigranulocytic. Those results are in 
accordance with previous studies (28;41;44;50;142).  
The mixed granulocytic phenotype had higher levels of fibrinogen, the lowest lung 
function and the highest degree of bronchial hyperresponsiveness to methacholine 
(Table 3 and 4). Like Hastie et al. (143), we identified patients with mixed 
granulocytic sputum inflammation exhibiting the lowest lung function. Moreover, the 
mixed granulocytic phenotype had higher serum fibrinogen values pointing to 
systemic inflammation in this subgroup. This interesting finding has not been reported 
so far in asthma but raised fibrinogen levels have been demonstrated to be 
associated with reduced FEV1 and increased risk of Chronic Obstructive Pulmonary 
Disease (COPD) in a population study (144). As for neutrophilic asthma there was no 
special characteristic that distinguishes this group from the other inflammatory 
patterns. In particular neutrophilic asthmatics did not display higher serum C-
Reactive Protein and fibrinogen levels. 
We looked at the exacerbation rate in the previous year according to asthma 
inflammatory phenotype. As compared to paucigranulocytic asthma (0.41 (0.29-0.43), 
n=203) the only inflammatory phenotype associated with increased exacerbation rate 
in the previous year was the eosinophilic phenotype (1.07 (0.76-1.37), n=211, 
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p<0.0001) while there was a trend for mixed granulocytic asthma (0.83 (0.24 – 1.43), 
n=14, p=0.08). Neutrophilic asthma did not differ significantly from paucigranulocytic 
and mixed granulocytic asthma (0.54 (0.24 – 0.83), n=80) but exhibited significantly 
lower exacerbation rate as compared to eosinophilic asthma (p=0.04). 
 
Table 3. Demographic characteristics according to inflammatory phenotypes. 
 Paucigranulocytic 
phenotype 
Eosinophilic 
phenotype 
Neutrophilic 
phenotype 
Mixed 
granulocytic 
phenotype 
N. 203 (40%) 211 (41.5%) 80 (15.7%) 14 (2.8%) 
Gender (M/F) 72/131 101/110 21/59 7/7 
Age, yrs 51 (21-86) 51 (19-87) 57 (21-84) 68 (31-88) 
Atopy (Y/N) 100/103 (49%) 140/71 (66%)* 48/32 (60%) 8/6 (57%) 
Smoking (Y/N) 48/155 (24%) 38/173 (18%) 12/68 (15%) 3/11 (21%) 
ICS therapy 
  Steroid naïve 
  Low dose 
  Moderate dose 
  High dose 
 
66 (32.5%) 
31 (15.3%) 
58 (28.6%) 
48 (23.6%) 
 
59 (28%) 
37 (17.5%) 
54 (25.6%) 
61 (28.9%) 
 
25 (31.3%) 
4 (5%)* 
23 (28.7%) 
28 (35%) 
 
3 (21.4%) 
1 (7.2%) 
3 (21.4%) 
7 (50%) 
*p<0.05, **p<0.001, ***p<0.0001 *Paucigranulocytic asthma is used as the comparator. ICS: 
inhaled corticosteroids. Low dose: ≤500µg/day beclomethasone; Moderate dose: 500-
1000µg/day beclomethasone; High dose: >1000µg/day beclomethasone.  
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Table 4. Functional and inflammatory characteristics according to inflammatory phenotypes. 
 Paucigranulocytic 
phenotype 
Eosinophilic 
phenotype 
Neutrophilic 
phenotype 
Mixed 
granulocytic 
phenotype 
N. 203 (40%) 211 (41.5%) 80 (15.7%) 14 (2.8%) 
IgE, kU/l 84 (1-7338) 211 (3-17183)*** 107 (2-7338) 346 (1-2063) 
Blood eosinophils, 
/mm³ 
160 (0-1220) 360 (0-3220)*** 170 (20-1020) 420 (190-
3040)*** 
Blood eosinophils, % 2 (0-13) 4.5 (0-26)*** 1.9 (0.2-15) 5 (1.3-30)*** 
Blood neutrophils, 
/mm³ 
4030 (76-11080) 4220 (1820-
15410) 
5000 (2070-
10440) 
4245 (3520-
6170) 
Blood neutrophils, % 59 (27-82) 55 (32-91)* 62 (42-80) 59 (43-68) 
FEV1, % predicted 90 ± 17 80 ± 20*** 79 ± 20*** 72 ± 14*** 
FEV1/FVC, % 77 ± 9 71 ± 10*** 72 ± 11*** 69 ± 9*** 
TLC, % predicted 99 ± 16 102 ± 18 102 ± 18 101 ± 14 
FRC, % predicted 103 ± 27 104 ± 19 119 ± 32 111 ± 22 
KCO, % predicted 90 ± 19 92 ± 21 91 ± 19 100 ± 10 
PC20, mg/ml 4.42 (0.13-16) 2.02 (0.025-16)** 3.22 (0.05-16) 1.08 (0.53-
2.2)** 
Reversibility, % 8 ± 9 15 ± 17** 8 ± 10 12 ± 10 
Sputum eosinophils, 
% 
0.4 (0-2.9) 18 (3-94)*** 0.2 (0-2.8) 4.3 (3-8)*** 
Sputum neutrophils, % 41 (0-76) 33 (0-76) 87 (77 – 100) 82 (76-92) 
Fibrinogen, g/l 3.1 (2-6.3) 3.1 (2-7.2) 3.3 (1.9-10) 4.1 (2.7-6.3)* 
CRP, mg/l 1.6 (0.2-14) 1.8 (0.2-14) 2.3 (0.2-10) 1.9 (1.1-6) 
FENO, ppb 16 (1-128) 53 (2-247)*** 22 (0-192) 41 (12-161)* 
ACQ 1.82 ± 1.15 2.16 ± 1.36* 2.09 ± 1.88 2.09 ± 1.16 
Global AQLQ 
- Emotion 
- Symptoms 
- Activity 
- Environment 
4.6 ± 1.3 
4.92 ± 1.35 
4.46 ± 1.46 
4.71 ± 1.36 
4.48 ± 1.50 
4.58 ± 1.34 
4.57 ± 1.63 
4.42 ± 1.43 
4.79 ± 1.44 
4.55 ± 1.55 
4.76 ± 1.46 
4.9 ± 1.76 
4.65 ± 1.54  
4.84 ± 1.49 
4.81 ± 1.67 
4.45 ± 1.74 
4.64 ± 1.83 
4.39 ± 1.5 
4.55 ± 1.80 
4.70 ± 2.15 
*p<0.05, **p<0.001, ***p<0.0001 *Paucigranulocytic asthma is used as the comparator. Data 
are presented as mean ± SD or median (range); PC20 is expressed as geometric mean 
(range). ACQ, Asthma Control Questionnaire; AQLQ, Asthma Quality of Life Questionnaire ; 
FENO, exhaled nitric oxide ; FEV1, forced expiratory volume in 1s; PC20, concentration 
required to provoke a fall in FEV1 of 20% or more; FVC, forced vital capacity. CRP, C-
Reactive Protein; FRC: Functional residual capacity; KCO: Carbon monoxide transfer 
coefficient; TLC: total lung capacity. Paucigranulocytic asthma is used as the comparator. 
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4.3 Factors associated with eosinophilic versus neutrophilic phenotypes  
As induced sputum is time consuming and not widely available, we aimed at 
determining factors associated with inflammatory phenotypes.  
4.3.1 Exhaled nitric oxide  
4.3.1.1 Introduction 
It has been claimed that exhaled nitric oxide could be regarded as a surrogate 
marker for sputum eosinophil count in patients with asthma. However the FENO 
threshold value that identifies a sputum eosinophil count ≥3% in an unselected 
population of patients with asthma has been poorly studied. Berry et al. found a 
threshold of 8.3ppb in non-smokers predicting a sputum eosinophil count >3% when 
measured at a flow rate of 250ml/s (49). ERS/ATS guidelines recommend however 
measuring exhaled nitric oxide at a flow rate of 50ml/sec.  
Moreover, both FENO and sputum eosinophil count were found to be strongly 
reduced by treatment with ICS (18;145). It is well recognised that smoking lowers 
FENO values in patients with asthma (146), and some studies have found that 
patients with asthma who smoke are less eosinophilic than non-smoking patients with 
asthma (147). Atopy was found to be associated with raised FENO irrespective of 
asthma (148) and is known to favour eosinophilic inflammation. There are, however, 
no data on how treatment with ICS, smoking and atopy may affect the relationship 
between FENO and sputum eosinophil count. 
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4.3.1.2 Results 
We performed a retrospective analysis of 295 unselected patients with asthma who 
underwent both FENO determination and successful sputum induction on the same 
visit. We determined FENO values that best identified a sputum eosinophil count 
≥3%, taking into account important covariates such as the dose of ICS, atopy, 
smoking status, age and gender. Asthmatics aged 15-84 years were recruited from 
our asthma clinic in University hospital of Liege between 1st October 2005 and 30th 
September 2008.  
We used Receiver-operating characteristic (ROC) curve and logistic regression 
analysis to assess the relationship between sputum eosinophil count and FENO. 
Logistic regression analysis assessed the relationship between the binary outcome 
(sputum eosinophil count ≥3%) and a set of covariates, individually or in combination. 
Covariates included FENO (log-transformed), age, gender, smoking, ICS and atopy. 
Cut-off points on the FENO scale were determined in each case so that there was a 
≥50% probability of a sputum eosinophil count ≥3%. The sensitivity, specificity, 
positive predictive value (PPV) and negative predictive value (NPV) were also 
calculated for each cut-off point from the original data. 
The demographic and functional characteristics of the patients are given in Table 5. 
For the whole group there was a significant positive relationship between the FENO 
level and the percentage of sputum eosinophil count (RS=0.54, p<0.0001; Fig 5).  
Despite this significant correlation, some patients showed marked discordance 
between the two markers. Patients with low sputum eosinophilia (<25% percentile) 
and high FENO levels (>75% percentile) were all atopic, non-smokers and receiving 
low doses of ICS (N=4). By contrast, for patients with high sputum eosinophilia 
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(>75% percentile) and low levels of FENO (<25% percentile), the only common 
distinctive feature was high doses of ICS (N=3).  
Using the ROC curve method we found that a FENO concentration >41 ppb yielded 
65% sensitivity and 79% specificity (AUC=0.78, p<0.0001) for identifying a sputum 
eosinophil count ≥3% in the whole population (Fig 6).  
 
Table 5. Demographic, functional and 
inflammatory characteristics of study patients   
(n=295). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data are presented as mean ± SD or median 
(IQR); PC20M is expressed as geometric mean 
(range). 
 
Characteristics  
Gender (M/F) 131/164 
Age, yrs 47.3 (14-83) 
Height, cm 168.6 ± 9.5 
Weight, kg 73.16 ± 15.9 
Atopy (Y/N) 208/87 
Smoking (Y/N) 58/237 
IgE, kU/L 169 (53 -472) 
Blood eosinophils, % 3.80 ± 3.4 
FEV1, % predicted 86 ± 19 
FEV1/FVC, % 75 ± 11 
PC20M, mg/ml 3.32 (0.025-16) 
Reversibility, % 13.1 ± 12.5 
Sputum eosinophils, % 1.8 (0.2-9.4) 
Sputum neutrophils, % 43.6 (17.8-68.8) 
FENO, ppb 31 (15-62) 
ACQ 1.84 ± 1.2 
AQLQ 4.77 ± 1.3 
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Fig 5. Evaluation of the relationship between sputum eosinophil count 
and exhaled nitric oxide (FENO) concentration in a cohort of 
unselected patients with asthma (n=295) by Spearman correlation. 
There was a highly significant correlation between these two 
parameters (p<0.0001, R=0.54). 
 
 
Fig 6. Receiver-operating characteristic curve (ROC) for the 
whole group to determine the exhaled nitric oxide (FENO) 
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value which best identified a sputum eosinophil count of 
≥3%. The optimum cut-off point was 41 ppb (point A, 
sensitivity 65% and specificity 79%). FENO levels >25 ppb 
gave a sensitivity of 78% and a specificity of 60% for 
identifying a sputum eosinophil count ≥3% (point B, positive 
predictive value (PPV) 59%, negative predictive value (NPV) 
79%). FENO values >50 ppb gave a sensitivity of 56% and a 
specificity of 86% for identifying a sputum eosinophil count 
≥3% (point C, PPV 75%, NPV 73%).  
 
This was confirmed by logistic regression analysis as we found that a threshold of 42 
ppb discriminated between eosinophilic and non-eosinophilic asthma with 63% 
sensitivity and 80% specificity (p<0.0001). 
Demographic, functional and inflammatory characteristics according to smoking 
status and the dose of ICS are given in Table 6. When taking the dose of ICS into 
account in nonsmokers, we distinguished four groups: steroid-naïve patients and 
patients receiving low doses of ICS (≤500 mg/day beclometasone), moderate doses 
(500-1000 mg/day beclometasone) and high doses of ICS (>1000 mg/day 
beclometasone). These groups had significantly different median FENO values, 
reaching 47 ppb, 46 ppb, 32 ppb and 24 ppb in steroid-naïve patients and those on 
low, moderate and high ICS doses, respectively (p<0.001, Table 6). By contrast, 
there was no significant difference in sputum eosinophil counts between the four 
groups (2.8% (IQR 0.8-14.4) in steroid–naïve patients, 1.8% (IQR 0-12.2) in patients 
on low-dose ICS, 1.0% (IQR 0-10.3) in patients on moderate doses and 1.8% (IQR 
0.3-7.4) in the high dose ICS group (p>0.05, Table 6). 
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Table 6. Demographic, functional and inflammatory characteristics of patients with regard to 
their smoking status and the dose of inhaled corticosteroids. 
  Smokers Non-smokers 
    Steroid naïve Low ICS Moderate ICS High ICS 
No. 58 70 41 67 59 
Gender (M/F) 31/27 26/44 17/24 33/34 24/35 
Age, yrs 45,7 (23-81) 42,3 (14-80) 47 (19-80) 47 (16-83) 50,5 (18-82) 
Height, cm 170,5±7,8 169±9,5 169,2±11 167±9,7 167±9,2 
Weight, kg 73,3±14 73±16 74,3±18 72,6±14 72,9±17,9 
Atopy 72% 80% 71% 67% 61% 
IgE, KU/l 185 (56-612) 166 (39-358) 210 (60-391) 180 (48-606) 132 (70-430) 
Blood eosinophils, % 3,6 ± 3,5 3,87 ± 3,4 3,94 ± 3,2 3,96 ± 3,5 3,26 ± 3,26 
FEV1, % pred 81,4±19 90,5±16 93,2±17,7 86,6±20,3 78,1±19 
FEV1/FVC, % 72±10,5 78,5±9 77,7±10,5 75±11,4 71,8±12 
PC20, mg/ml 4,23(0,025-22) 2,17(0,05-22) 6,6(0,302-22) 3,93(0,2-22) 2,3(0,101-22) 
Reversibility,% 15±11 15,3±14,8 12,1±8,5 13,3±14,3 11,1±11,7 
Sputum eosinophils, % 1,7 (0,2-8) 2,8 (0,8-14,4) 1,8 (0-12,16) 1(0-10,3) 1,8(0,25-7,35) 
Sputum neutrophils, % 43,1(17,6-63,8) 41,7(13-65,8) 32(16,4-49,5) 45(22,7-73,9) 52,5(29,1-75,1) 
FENO,ppb 17(12-37) 47(23-87) 46(21-75) 32(13-61) 24(12-45) 
ACQ 2,36±1,2 1,57±1,1 1,34±0,9 1,69±1,1 2,16±1,3 
AQLQ 4,39±1,28 5,18±1,17 5,15±1,1 4,74±1,37 4,4±1,35 
 
Data are presented as mean ± SD or median (IQR); PC20M is expressed as geometric mean 
(range). 
 
Using logistic regression we found that the FENO threshold associated with sputum 
eosinophils ≥3% for patients receiving high doses of ICS was significantly lower (27 
ppb) than that of steroid-naïve patients or those receiving low and moderate doses of 
ICS (48 ppb, p=0.028, Table 7). 
Median FENO in atopic subjects was 1.3 times higher (34 ppb) than in non-atopic 
patients (26 ppb), which is close to that reported by Travers et al. (1.2 times, 
p=0.011) (149). By contrast, the sputum eosinophil count did not differ between 
atopic and non-atopic asthmatic subjects (median 1.8% vs 2%, p=0.543). Using 
logistic regression, atopic patients had a significantly greater FENO threshold value 
(49 ppb) than non-atopic patients (30 ppb, p=0.049) to identify sputum eosinophils 
≥3% (Table 7). 
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Table 7. Simple logistic regression analysis assessing the effect of a high dose of ICS and 
atopy on the FENO threshold for identifying sputum eosinophilia ≥3%. 
Characteristics FENO 
cut-off 
(ppb) 
Specificity 
(%) 
Sensitivity 
(%) 
PPV (%) NPV (%) p-
value 
High dose ICS Yes 
No 
27 
48 
62 
84 
76 
56 
59 
72 
78 
72 
0.028 
Atopy Yes 
No 
49 
30 
84 
64 
56 
74 
72 
60 
72 
77 
0.049 
Smoking Yes 
No 
28 
46 
62 
82 
76 
58 
59 
70 
78 
73 
0.066 
Male 
 
Yes  
No 
37 
48 
71 
84 
66 
56 
63 
72 
74 
72 
0.24 
Age ≥ 40 
< 40 
43 
42 
80 
79 
62 
64 
69 
69 
74 
75 
0.87 
 
The FENO level in smokers was significantly lower than in non-smokers (median 17 
ppb for smokers vs 35 ppb for non-smokers, p=0.003). The median FENO level for 
non-smokers was two times higher than in current smokers, which was higher than 
1.18 obtained by Travers et al. (149) but in line with the results of Michils et al. (150). 
In contrast, the median (IQR) sputum eosinophil count did not differ significantly 
between smokers and non-smokers (1.7 (0.2-8) vs (1.8 (0.2-10.7); p=0.765). After 
logistic regression the FENO level that identified a sputum eosinophil count of ≥3% 
was lower in smokers than in non-smokers (28 ppb vs 46 ppb, p=0.066, Table 7). 
The median FENO value was 1.33 times greater in men than in women (36 ppb vs 27 
ppb, p=0.009), which is in keeping with the results of Travers et al. (1.24 times)(149). 
The sputum eosinophil count was greater in men than in women (2.9% vs 1.5%, 
p=0.042). However, the FENO threshold that best identified a sputum eosinophil 
count of ≥3% was not significantly different between men and women (Table 7). 
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Likewise, age did not influence the relationship between FENO and sputum 
eosinophils. 
When combining all variables into the logistic model, FENO (p<0.0001), high-dose 
ICS (p=0.019) and smoking (p=0.044) were independent predictors of sputum 
eosinophilia and there was a trend for atopy (p=0.086), but age and gender were not 
significant (Table 8). The optimal cut-off point for FENO associated with a sputum 
eosinophil count >3% ranged from 15 ppb for smoking non-atopic patients receiving 
a high dose of ICS to 58 ppb for non-smoking atopic patients not treated with a high 
dose of ICS. 
 
Table 8. Cut-off points for FENO for predicting a sputum eosinophil count ≥3% after multiple 
logistic regression analysis. 
Smoking Atopy High dose 
of ICS 
FENO cut-off 
(ppb) 
Specificity 
(%) 
Sensitivity 
(%) 
PPV 
(%) 
NPV 
(%) 
No No No 38 74 66 65 75 
No No Yes 24 59 78 58 79 
No Yes No 58 88 48 74 70 
No Yes Yes 35 71 70 64 76 
Yes No No 23 58 78 58 78 
Yes No Yes 15 37 94 52 89 
Yes Yes No 33 68 70 62 76 
Yes Yes Yes 20 54 85 58 83 
When combining all variables into the logistic model, we found that only FENO (p<0.0001), 
smoking (p=0.044) and ICS (p=0.019) were significant predictors of sputum eosinophil count 
3 %. When atopy was added, the p-value was not significant although a trend was observed 
(p=0.086) (For more details on calculation, see on-line supplement). 
 
We compared our FENO values in patients with asthma with those expected based 
on the equation proposed by Dressel et al. (151) in a general population, taking into 
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account the height, gender, atopy and smoking status. It appeared that our observed 
values were much higher than expected, which highlights the importance of asthma 
as a major factor contributing to the rise in FENO (Table 9). 
 
Table 9. Comparison of exhaled nitric oxide (FENO) values measured in patients with 
asthma with those expected based on the formula proposed by Dressel et al. (151) taking 
into account height, gender, atopy and smoking status*. 
 
FENO value 
based on Dressel 
et al. (151) 
Geometric mean FENO 
value for our 
population with asthma 
Optimum cut-off point 
for predicting a sputum 
eosinophil count ≥3% 
Males, smokers, atopy 20 50 31 
Males, non-smokers, 
atopy 33 62 
 
51 
Males, smokers, no 
atopy 14 53 
 
22 
Males, non-smokers, no 
atopy 21 48 
 
33 
Females, smokers, atopy 16 35 
 
39 
Females, non-smokers, 
atopy 25 47 
 
66 
Females, smokers, no 
atopy 10 14 
 
26 
Females, non-smokers, 
no atopy 16 39 
 
40 
    
 
𝐹𝑒𝑁𝑂(𝑝𝑝𝑏)∗ = 17.493 × (1.496 𝑖𝑓 𝑎𝑡𝑜𝑝𝑦) × (0.627 𝑖𝑓 𝑠𝑚𝑜𝑘𝑒𝑟) × (1.235 𝑖𝑓 𝑖𝑛𝑓𝑒𝑐𝑡𝑖𝑜𝑛)
× (1.174 𝑖𝑓 𝑚𝑎𝑙𝑒) × 1.113 × (
ℎ𝑒𝑖𝑔ℎ𝑡 − 170
10
) 
4.3.1.3 Discussion 
Although the debate is not over, it is generally accepted that FENO has the potential 
to assess the phenotype of airway inflammation. Like those of Berry et al. (49), our 
data show that FENO can effectively identify sputum eosinophilia in a large cohort of 
unselected patients with asthma. There is, however, clear variation in the threshold 
associated with a sputum eosinophil count of ≥3% depending on treatment with ICS, 
atopy and smoking status. 
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The technique of induced sputum that allows collection of airway cells has 
contributed to the emergence of the concept of asthma phenotypes (152). Although 
introduced in the early 1990s, the technique has not been widely adopted into clinical 
practice, probably because it is technically demanding and time-consuming. 
Given the recognised clinical value of sputum eosinophil count, we wondered 
whether FENO measured at a flow rate of 50 ml/s could effectively identify a sputum 
eosinophil count ≥3% in a large cohort of unselected patients with asthma with 
different disease severity. Overall we found that FENO was a valuable measurement 
to identify eosinophilic asthma with a threshold value of 41 ppb, having sensitivity 
and specificity of 65% and 79% respectively. This threshold is twice as high as the 
level recommended for an asthma diagnosis (20 ppb) but quite close to the level that 
Smith et al. claimed to predict a positive response to ICS (47 ppb)(132). This is also 
in keeping with the fact that having a sputum eosinophil count of at least 3% is 
associated with a clinical response to short-term treatment with ICS. Coincidently, our 
threshold of 41 ppb appears to be the same as the upper limit of the 90% CI found in 
a normal population (149). There is an emerging consensus that FENO values >50 
ppb indicate active eosinophilic airway inflammation (153). Conversely, FENO values 
<25 ppb are associated with minimal airway eosinophilia. According to our data, 
FENO <25 ppb has a negative predictive value of 79% for significant airway 
eosinophilic inflammation and FENO >50 ppb has a positive predictive value of 75% 
to identify sputum eosinophilia. 
It is well established that chronic treatment of asthma with ICS results in a reduction 
in airway eosinophilia (18;154) together with a fall in FENO (145;155;156). How this 
treatment may affect the relationship between sputum eosinophilia and FENO 
remains unclear, however. Our data indicate that FENO is more sensitive than the 
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sputum eosinophil count to ICS as patients receiving higher doses of ICS had lower 
FENO values than the other groups, a phenomenon not observed with the sputum 
eosinophil count. Consequently, the FENO threshold associated with sputum 
eosinophilia ≥3% will be lower in patients receiving high doses of ICS than in those 
not treated or receiving low or medium doses of ICS. 
In agreement with previous studies (148), the influence of atopy was evident in our 
study with a 30% increase in FENO in atopic compared with non-atopic patients with 
asthma. On the other hand, the sputum eosinophil count was similar in both groups. 
Consequently, the FENO threshold associated with sputum eosinophilia was found to 
be greater in atopic patients with asthma than in non-atopic patients with asthma. 
Interestingly, our data show that sputum eosinophilia may be present in subjects with 
asthma who smoke. Indeed, the median value in asthmatics who smoke was not 
significantly lower than that in the non-smoking group, which is consistent with the 
findings of Boulet et al. (157). There are no data showing that starting to smoke 
reduces the sputum eosinophil count in patients with asthma. There are, however, 
data showing that smoking cessation in asthma does not impact on the sputum 
eosinophil count (158). In contrast, the FENO levels were clearly lower in patients 
with asthma who smoke, which confirms the results of a previous study (146). This 
may be explained by partial irreversible inhibition of nitric oxide synthase by cigarette 
smoke extract (159;160), or by conversion of nitric oxide to peroxynitrite by 
superoxide release from neutrophils (161). As tobacco influences FENO and the 
sputum eosinophil count differently, it therefore changes the FENO cut-off value. As 
expected, we found higher FENO levels in men than in women. Interestingly, the 
sputum eosinophil count was lower in women than in men, an observation not 
previously reported and in keeping with the higher proportion of neutrophilic asthma 
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in women (13). The reasons for this are unclear at present but might be linked to 
different immunological mechanisms governing airway inflammation (12). Although 
gender may influence both the FENO and the sputum eosinophil count, it does not 
alter the relationship between these two variables. As several parameters were 
shown to influence the relationship between FENO and sputum eosinophils, a 
multiple logistic regression approach was used to determine the most useful cut-off 
point in a patient. It confirmed the importance of high-dose ICS and smoking and, to 
a lesser extent, atopy. We found that the optimal cut-off points varied from 15 ppb for 
smoking non-atopic patients receiving a high dose of ICS to 58 ppb for non-smoking 
atopic patients not treated with a high dose of ICS. The gap between these two 
extremes is large and ought to be taken into account in the interpretation of airway 
inflammation. Some of our patients had paucigranulocytic asthma (124) and still 
exhibited raised FENO levels. This discordance might be explained by inflammation 
which has not spilled over into the airway lumen, such that induced sputum is 
negative for eosinophils while this cell type still persists in the airway wall. In these 
patients, monitoring of FENO could be more informative than measuring sputum 
eosinophils. While it is a reasonable assumption that our derived FENO cut-off values 
will be applicable to the general asthma population, further work is required to 
validate this in practice as we did not divide our dataset into training and testing 
groups. 
We can conclude that FENO is able to identify the presence of sputum eosinophilia in 
unselected patients with asthma with reasonable accuracy as long as thresholds are 
adjusted for high doses of ICS, atopy and smoking status. 
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4.3.2 Blood eosinophils, IgE and FEV1/FVC 
For the 508 patients who underwent a successful sputum induction between October 
2005 and June 2011, there was a significant positive relationship between blood 
eosinophil count, either expressed as percentage or absolute value, and percentage 
of sputum eosinophil count (r=0.6, p<0.0001; r=0.6, p<0.0001; respectively; Fig 7). 
We constructed ROC curves to determine the concentration of blood eosinophils or 
neutrophils that best identified a sputum eosinophil count ≥3% or a sputum neutrophil 
count ≥76% respectively. We found that a blood eosinophil count ≥220/mm³ yielded 
77% sensitivity and 70% specificity (Area under the curve (AUC) = 0.79, p < 0.0001, 
Fig 8) for identifying a sputum eosinophil count ≥3% in the whole population. By 
constructing a ROC curve we found that a cut-off value of 3% for percentage of blood 
eosinophils was able to identify the presence of a sputum eosinophil count ≥3% with 
75% sensitivity and 73% specificity (AUC=0.81, p< 0.0001, Fig 9). The measure of 
blood eosinophils was as efficient as FENO (cut-off=41 ppb, AUC: 0.79, p<0.0001) 
for identification of sputum eosinophilia ≥3%. The comparison of the AUC for both 
tests failed to demonstrate a significant difference (p=0.77).  
We further sought to determine the factors associated with sputum eosinophilic 
phenotype. The logistic regression analysis was used to assess the relationship 
between the binary outcome (sputum eosinophil count ≥3%) and a set of covariates 
(gender, age, height, weight, atopy, smoking status, IgE, blood eosinophil and 
neutrophil count, FEV1%, FEV1/FVC, TLC, FRC, KCO, PC20M, Reversibility, 
Fibrinogen, CRP, FENO, ACQ, AQLQ, ICS therapy). When combining all variables 
into the model, percentage of blood eosinophils (logit-transformed; p<0.0001), 
FEV1/FVC (p=0.0021), FENO (log-transformed; p<0.0001), and IgE (log-transformed; 
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p=0.0085) were independent factors associated with the presence of sputum 
eosinophilic inflammation (Table 10).  
 
 
Using those variables, we established a formula to compute the probability () of a 
sputum eosinophil count ≥ 3%:  
𝜋 =
𝑒𝑥𝑝(𝐿)
1 + 𝑒𝑥𝑝(𝐿)
 
where 𝐿 = 2.92 + 1.218 × 𝑙𝑛
𝐵𝑙𝑜𝑜𝑑 𝑒𝑜𝑠%
100−𝐵𝑙𝑜𝑜𝑑 𝑒𝑜𝑠%
+ 0.217 × 𝑙𝑛(𝐼𝑔𝐸)   − 0.039 ×
𝐹𝐸𝑉1
𝐹𝑉𝐶%
+ 0.844 × 𝑙𝑛(𝐹𝐸𝑁𝑂) 
π: probability of sputum eosinophil count ≥ 3%. 
Blood eos%: Blood eosinophil count in %. 
 
The ability of the equation to predict sputum eosinophilia was tested in an 
independent population of 138 asthmatics recruited between July 2011 and May 
2012 who underwent FENO, spirometry, sputum induction and gave a blood sample. 
The demographic, functional and inflammatory characteristics of the validation 
population were similar to those of the study population. 
The agreement between predicted and observed value gave a Cohen Kappa’s 
coefficient of 0.59 (p<0.0001, lower limit of confidence interval =0.43). The specificity 
and sensitivity were 62.7% and 93.7% respectively while the PPV was 67% and the 
NPV was 93%. 
Among the factors shown to contribute to airway eosinophilia, blood eosinophils 
came first when performing a multiple logistic regression. There are few studies 
assessing the ability of blood eosinophils to identify airway eosinophilic inflammation. 
Previous studies showed that peripheral blood eosinophil count was correlated with 
bronchoalveolar lavage eosinophil count (162) and sputum eosinophil count (163-
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165). These studies have, however, investigated a limited number of asthmatics and 
did not provide any threshold value of blood eosinophils as marker of airway 
eosinophilia. The American multicentre study found a threshold value of 220/mm³ as 
the best compromise for predicting sputum eosinophil count ≥2% (140). Another 
recent study conducted in COPD showed that a cut-off of 2% peripheral blood 
eosinophils had a sensitivity of 90% and specificity of 60% for identifying a sputum 
eosinophilia of greater than 3% at exacerbation. In our study, we confirmed the 
correlation between blood and sputum eosinophilic inflammation in a large cohort of 
patients. We found the best threshold to be 220/mm³ and 3% and these thresholds 
were as effective as FENO at predicting uncontrolled airway eosinophilic 
inflammation. Our findings are in keeping with those recently reported by McGrath et 
al. (140). Compared to blood eosinophils, FENO has however the advantage of 
giving immediate results and its measurement is more comfortable to the patient. 
In this study the performance (threshold, sensitivity, specificity) of FENO to identify 
sputum eosinophil count is very similar to the one we reported previously (166). The 
fact that FENO and blood eosinophil counts came out as independent predictors of 
sputum eosinophilia in the multiple logistic regression suggests that these two 
markers reflect different mechanisms promoting the recruitment of eosinophils into 
the airways. Other independent factors to be shown associated with prominent 
sputum eosinophilia are FEV1/FVC and total serum IgE level. Previous studies have 
shown that FEV1/FVC, an index of airway narrowing, was correlated to sputum 
eosinophilia (37) and eosinophilic asthma has been recognised to be frequently 
associated with atopic disease (13;24). In our study, total serum IgE levels were 
however best predictor of sputum eosinophilia than atopy per se, in line with a recent 
study (140). From the biological properties of IgE it can be speculated that high tissue 
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IgE may prime local mast cells and activate them even without intervention of 
allergens (167). In this view it is interesting to note that airway mast cell activation 
demonstrated by tryptase release is a phenomenon found to be associated with 
sputum eosinophils in asthma (168) and COPD (169). 
 
Fig 7. Relationship between sputum eosinophil count and blood eosinophil 
count in a cohort of unselected patients with asthma (n=508) by Spearman 
correlation. There is a significant correlation between these two parameters 
(p<0.0001, Rs= 0.6). AV: absolute value of blood eosinophils (/mm³). 
 
 
 
 
0 20 40 60 80 100
0
500
1000
1500
2000
2500
3000
3500
Sputum eosinophil count (%)
B
lo
o
d
 e
o
s
in
o
p
h
il 
c
o
u
n
t 
(/
m
m
³)
85 
 
 
Fig 8. Receiver-operating characteristic (ROC) curve 
for the whole group to determine the blood eosinophil 
count value that best identified a sputum eosinophilia 
≥3%. The optimum cut-off point was 220/mm³ 
(Sensitivity 77%, specificity: 70%, AUC: 0.790, 
p<0.0001). 
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Fig 9. Receiver-operating characteristic (ROC) curve 
to determine the blood eosinophil count percentage 
that best identified a sputum eosinophilia ≥3%. The 
optimum cut-off point was 3% (Sensitivity: 75%, 
specificity: 73.4%, AUC: 0.81, p<0.0001). 
 
 
Table 10. Independent predictors of sputum eosinophilia. 
Parameter β SE p-value 
Logit Blood eosinophils, % 1.218 0.19 P<0.0001 
Ln IgE 0.217 0.08 P=0.0085 
FEV1/FVC, % -0.039 0.01 P=0.0021 
FENO 0.844 0.16 P<0.0001 
Ln, Natural logarithm; FEV1, Forced expiratory volume in 1 s; FVC: Forced vital capacity; 
FENO, exhaled nitric oxide; SE: standard error.  
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4.3.3 Factors associated with neutrophilic phenotype 
4.3.3.1 Blood neutrophils, age and FRC 
The same approach as for eosinophils was used to predict the presence of sputum 
neutrophils. 
There was a weak correlation between sputum and blood neutrophil count taken in 
percentage (r=0.19, p=0.0015) but not in absolute value (r=0.19, p=0.11). Despite 
statistically significant correlation between sputum and percentage blood neutrophils, 
the strength of the relationship was rather poor. 
Using the ROC curve method, we found a cut-off of 4960/mm3 and 66% respectively 
giving a sensitivity of 49% and 37%, a specificity of 70% and 90%, p=0.03 and 
p=0.003, AUC=0.59 and AUC=0.63 respectively. 
However, when combining all variables into the logistic model, age (p=0.006) and 
Functional residual capacity (FRC, p=0.001) were independent factors associated 
with sputum neutrophilia. The multiple logistic regression analysis demonstrated the 
inability of blood neutrophils to predict uncontrolled sputum neutrophilic inflammation.  
 
The formula to compute the probability () of a sputum neutrophil count ≥ 76% was: 
𝜋 =
𝑒𝑥𝑝(𝐿)
1 + 𝑒𝑥𝑝(𝐿)
 
where 𝐿 = −5.32 + 0.032 × 𝑎𝑔𝑒 + 0.022 × 𝐹𝑅𝐶 
π: probability of sputum neutrophil count ≥ 76%. 
 
To test the ability of the equation to predict sputum neutrophilia, we recruited a 
validation population of 178 asthmatics who underwent spirometry and sputum 
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induction. The agreement between predicted and observed value of sputum 
neutrophil counts gave a Cohen Kappa’s coefficient of 0.24 (p<0.0001, lower limit of 
confidence interval =0.12). The specificity and sensitivity were 21% and 97% 
respectively. Patients receiving moderate to high dose ICS had higher sputum 
neutrophil counts (47.3%) than patients receiving low dose ICS (38.8%, p=0.017). 
Smokers did not have significantly higher proportion of neutrophils in their sputum 
(Median 48.9%) than ex-smokers (Median 50.6%, p=0.68) or never-smokers (Median 
44%, p=0.19). However, neither smoking status nor the dose of inhaled 
corticosteroids was able to predict elevated sputum neutrophil count. 
The accumulation of airway neutrophils has been reported to be directly associated 
with the activation of circulating neutrophils in response to the chemokine Interleukin-
8 (169-171). Baines et al. found a correlation between plasma neutrophil elastase 
and neutrophilic airway inflammation (172). Such data suggest that airway 
neutrophilic accumulation could be due to an enhanced neutrophil activation and 
migration to the airways independently of the number of circulating cells. Moreover, it 
has been shown that neutrophils can be retained in the pulmonary microvasculature 
due to their low deformability, resulting in a higher concentration than in the systemic 
circulation. It is thought that this high concentration of the cells facilitates their 
effective recruitment to sites of inflammation (173). It seems likely that many could 
leave the circulation by chemoattraction, entering the lung without necessarily having 
a detectable effect on circulating levels. From a multiple logistic regression two 
factors came out as being independently associated with sputum neutrophilia. In 
keeping to what was found by Thomas et al. in healthy subjects (121) and Woodruff 
et al. (41) in asthmatics, age appeared to be a critical factor in our cohort with sputum 
neutrophilia rising with age. In addition to age we also found that FRC was an 
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independent factor. This suggests that airway neutrophils may contribute to reduction 
of inspiratory capacity seen in some asthmatics. Accordingly, two paediatric studies 
reported that percentage neutrophils in bronchoalveolar lavage directly correlated 
with air trapping (FRC) in children with cystic fibrosis (174;175). However, neither 
smoking status nor the dose of inhaled corticosteroids was able to predict the 
presence of sputum neutrophil count. 
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4.3.4 Volatile organic compounds (VOCs) 
We wanted to determine the ability of VOCs detection in exhaled air to discriminate 
between paucigranulocytic and eosinophilic/neutrophilic asthma. Our project involved 
basic experimental and in vivo studies. Chemical identification of the compounds 
released by eosinophils and neutrophils in vitro gave potential candidates to check in 
asthmatic patients for asthma phenotyping. 
4.3.4.1 In vitro study 
We measured VOCs released by neutrophils and eosinophils in vitro. Eosinophils 
and neutrophils were isolated from 27ml blood of 16 healthy non-smokers by gradient 
centrifugation using lymphoprep. Eosinophils were isolated from neutrophils by 
immunomagnetic cell separation (MACS) using anti-CD16 micro beads. CD16 
positive cells remained in the column while the other were collected in the falcon 
tube. The average absolute number of eosinophils and neutrophils upon isolation 
was 3.5 x 106 and 19.4 x 106 respectively. Cells were incubated in medium RPMI at 
37°C and activated with phorbol 12-myristate 13-acetate (100ng/ml). A study 
published in 2003 effectively showed that eosinophils and neutrophils generated 
extracellular oxygen radicals in response to activation by PMA and that the best 
slope of release was obtained with a concentration of 100ng/ml (176). 
The viability of the cells was evaluated using trypan blue and mitochondrial activity 
testing. Headspace air was sampled at time 30’, 60’ and 90’ by introduction of ultra-
pure nitrogen in closed flasks at a flow rate of 200 ml/min during 10 min (Fig 10). 
Each experiment was done 10 times. The air was pushed out onto a carbon tube and 
the total amount of trapped VOCs (volatome) was analysed by time-of-flight GC-MS. 
From the 2116 compounds presents in the volatome, those present in at least 8% of 
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the samples (1123 compounds) were used for further analysis. Leave-one-out 
method was used as a kind of cross-validation analysis as it is a statistical technique 
of choice when the number of samples is small. For the leave-one out method, one 
sample is left out for each statistical analysis and each sample is used once as 
validation. Discriminant analysis (SPSS statistics19) showed that 2 VOCs were able 
to distinguish between unactivated eosinophils and unactivated neutrophils with 85% 
correct classification of original data set and cross-validated observations. Chemical 
identification of both compounds was 3-methylfuran and benzylalcohol, with higher 
levels in the neutrophilic culture as compared to eosinophilic culture. Benzylalcohol is 
very interesting as it was also found to be discriminative in vivo between healthy 
controls and asthmatics by Ibrahim et al. (177). 3-methylfuran has already been 
detected in human breath with a significant difference between healthy controls and 
patients with lung cancer (178).  
5 VOCs were able to distinguish between both activated culturing types with 100% 
and 96% correct classification in original and cross-validated sets respectively. 
Keeping only the 2 most important compounds gave 83% correct classification of the 
samples. Chemical identification showed that 1-H-indenol and 2-Butoxyethanol 
discriminated between activated eosinophils and neutrophils.  
From this first part of the in vitro study we concluded that analysis of VOCs seems 
very promising in discriminating between eosinophilic and neutrophilic inflammation 
but needed further development and in vivo confirmation. 
We also looked at the VOCs that discriminated between activated and unactivated 
cells. For eosinophils, p-dichlorobenzene (peak 254) gave 84% correct classification 
of original and cross-validated sets. Our hypothesis is that when eosinophils are 
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activated in vitro, they release EPO that is responsible for chlorinated agent 
production. The main role of eosinophil peroxidase was shown to be the production 
of oxygen radicals to kill parasites. Eosinophil peroxidase has been shown to be able 
to use halides or pseudohalides (Cl-, Br-, I-, SCN-) and H2O2 to generate cytotoxic 
hypohalous acids (179). EPO has also been shown to generate preferentially 
hypobromous acid and that hypochlorous acid are essentially produced when pH is 
lower than 6 or if the medium Cl- concentration increased (179).  
 
 
Fig 10. Sampling of the head space of flasks containing activated eosinophils or neutrophils.  
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We further identified VOCs able to distinguish between activated and unactivated 
neutrophils. Peak 842, Benzylalcohol and 6,10-dimethyl-5,9 dodecadien-2-one were 
the three VOCs able to discriminate between unactivated and activated neutrophils. 
We were unable to identify the component corresponding to peak 842. A possible 
explanation could be that this compound is not in the NIST Library or that the initial 
compound structure has been modified during heating of the tube and is no longer 
recognisable.  
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4.3.4.2 In vivo VOCs study 
276 asthmatics were sampled with 3328 volatile organic compounds detected. From 
those patients, 122 exhibited eosinophilic asthma, 90 had paucigranulocytic asthma, 
50 neutrophilic asthma and 14 mixed granulocytic asthma. Their demographic 
functional and inflammatory characteristics (Table 11) were similar to those of the 
prospective asthmatic population studied in chapter 4.5 (Table 18-19).  
 
Table 11. Demographic and functional characteristics of 276 
asthmatics recruited for the VOCs study 
Characteristics 
N. 
Age (yrs) 
 
276 
50 ± 15 
Gender (% of female) 59 
Smokers (%) 
Ex-smokers (%) 
Non-smokers (%) 
18.5 
36 
45.5 
FEV1 (% pred) 82 (24-133) 
 
Time-of-flight mass spectrometry was used to identify components (peaks) available 
in the samples (Fig 11). When comparing volatile organic compounds present in the 
exhaled air of paucigranuloctytic to those present in eosinophilic asthmatics, 3 
components (P337, P903 and P923, Fig 12) were shown to be good discriminators. 
The chemical nature of these compounds cannot be unveiled yet although 2 of them 
were identified using the NIST Library. P923 remained undetermined. A possible 
explanation could be that this compound is not in the NIST Library or that the initial 
compound structure has been modified during heating of the tube and is no longer 
recognisable. 
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Fig 11. Example of exhaled air sample as measured by thermo-
desorption GC-MS. 
 
 
Fig 12. P337, P903 and P923 are good driscriminator between eosinophilic and 
paucigranulocytic asthma. P# is a consecutive compound number of the original 
data matrix with the column number. 
 
 
There have been previous studies using eNose to diagnose asthma vs COPD (63) or 
using GC-MS VOCs or eNose analysis to discriminate between asthmatics vs healthy 
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subjects (180;181). The study of Montuschi has also compared the asthma 
diagnostic performance of FENO, lung function testing and eNose showing that the 
best performance was obtained by combining eNose and FENO (182). Robroeks et 
al. conducted a study demonstrating that a combination of different exhaled VOCs 
was able to predict exacerbations in childhood asthma (183). Moreover Ibrahim and 
colleagues demonstrated on a small population of asthmatics that VOCs profiles 
were able to diagnose sputum eosinophilia (177). However, our study is the first 
attempt to characterise VOCs according to sputum eosinophilic, neutrophilic and 
paucigranulocytic phenotype in a large population of asthmatics. If we accept the 
definition of asthma being symptoms combined to excessive airway variability, we 
believe that it is very unlikely that such a complex physiological disorder may be 
captured by spotting individual biological compounds in the exhaled air. By contrast, 
because they may reflect some inflammatory pathway we think that VOCs analysis is 
essentially useful to characterise the inflammatory phenotype of asthma rather than 
to diagnose asthma itself. This could have treatment implications for patients in 
whom a quick diagnosis of asthma phenotype could predict the response to 
treatment. 
 
We further compared the volatile organic compounds presents in the exhaled air of 
neutrophilic and paucigranulocytic asthmatics to identify discriminative VOCs for the 
neutrophilic phenotype. We found that P2622 and P2853 were volatile organic 
compounds able to distinguish asthmatics with increased neutrophil counts as 
compared to pauci-granulocytic asthma (Fig 13). 
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Fig 13. Two peaks are associated with a significant discriminant power. P# is a 
consecutive compound number of the original data matrix with the column 
number. 
 
We tested the ability of VOCs to discriminate between eosinophilic and neutrophilic 
asthma. We showed that Peak 253 and 1913 were able to discriminate between 
eosinophilic and neutrophilic airway inflammation.  
Using canonical discriminant functions, we discriminate between neutrophilic asthma 
(group 1, blue), eosinophilic asthma (group 2, green) and paucigranulocytic asthma 
(group 3, yellow) (Fig 14).   
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Fig 12. Canonical discriminant functions. 
 
 
The discriminative capacity of VOCs has of course to be confirmed in a prospective 
study. We would like to contribute to the development of a small device allowing a 
quick measurement of airway inflammation that could be used by asthmatics to adapt 
their treatment and decrease the risk of exacerbations. 
Ibrahim et al. (177), using gas chromatography and mass spectrometry in a small 
population of 35 asthmatics, found a model using 15 VOCs that was able to 
discriminate between asthmatics and healthy controls with 86% accuracy. In this 
study they also sought to discriminate breath samples from eosinophilic as compared 
to non-eosinophilic asthmatics and from neutrophilic as compared to non-neutrophilic 
asthmatics. They found that three principal components had a classification accuracy 
of 83% for discrimination between patients exhibiting induced sputum eosinophil 
counts <2% (n=10) as compared to ≥2% (n=8) with a sensitivity of 75% and a 
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specificity of 90%. When comparing neutrophilic (≥40%, n=8) versus non-neutrophilic 
asthma (<40%, n=10), one principal component was able to discriminate between 
both groups with 72% accuracy. The limitation of this study was the low number of 
patients studied and the choice of the neutrophilic threshold which is well inside the 
normal range for this cell type (118). 
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4.4 Exhaled nitric oxide: a marker of airway hyperresponsiveness 
4.4.1 Introduction 
Some studies have suggested that FENO may be helpful in diagnosing asthma but it 
remains debated. We conducted a field study assessing the potential of fractional 
exhaled nitric oxide, measured at a flow rate of 50 ml/s in steroid-naïve patients with 
suspected asthma sent by respiratory physicians to a routine function laboratory to 
perform a methacholine challenge.  
Asthma diagnosis is usually based on symptoms such as cough, breathlessness, 
dyspnoea and wheezing together with the demonstration of airflow variability. The 
airway inflammatory component of the disease is an important feature which is an 
integral part of the asthma definition (5). Both sputum eosinophil count and FENO 
have been proposed as a useful diagnostic tool in mild to moderate asthma. There is 
a need for a simple, quick and reliable test in those patients with suggestive 
symptoms of asthma.  
Early studies have suggested that fractional exhaled nitric oxide, measured at a flow 
rate of 200ml⁄s cut-off of 16ppb may help to identify patients with bronchial 
hyperresponsiveness to histamine or reversibility to β2-agonist among those 
presenting with chronic respiratory symptoms and normal baseline lung function (73). 
Airway hyperresponsiveness assessed by methacholine challenge is time consuming 
and unpleasant to the patient whereas FENO measurement is easy to perform and 
provides immediate results. The purpose of our study was to see how FENO 
measured at a flow rate of 50 ml/s may actually reflect the presence of methacholine 
bronchial hyperresponsiveness assessed by the provocative concentration that 
causes a 20% fall in FEV1 (PC20M) in patients referred by chest physicians for 
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asthma diagnosis to a routine laboratory function. We also sought to establish how 
different types of respiratory symptoms relate to FENO and PC20M. 
We conducted a prospective study on a series of 237 patients recruited from the 
University Hospital of Liege between 13th March 2009 and 30th December 2009. 
These patients were addressed by their respiratory physician for a methacholine 
challenge to detect asthma. Subjects referred to methacholine challenge were those 
in whom the bronchodilating test failed to demonstrate reversible airways obstruction 
or those in whom baseline spirometric values were normal giving a low probability for 
a bronchodilating test to be significant. The patients studied here had either baseline 
FEV1≥80% predicted and FEV1/FVC ratio ≥70% or bronchodilation <12% from 
baseline and 200ml after 400 µg inhaled salbutamol in case of baseline FEV1 was 
<80% predicted or FEV1/FVC ratio <70%. Patients already receiving inhaled 
corticosteroids were excluded from the study. The demographic and functional 
characteristics of the 174 corticosteroid-naïve patients are summarised in Table 12. 
 
Table 12. Demographic, functional and inflammatory 
characteristics for 174 steroid-naïve patients. 
No. 174 
Gender (M/F) 72/102 
Age, yrs 41 ± 16 
Atopy (Y/N) 84/90 
Current Smoking (Y/N) 59/115 (34%) 
PC20 <16mg/ml (Y/N) 82/92 
FEV1, % predicted 97 ± 13 
FVC, % predicted 100 ± 14 
FEV1/VC, % 83 ± 7 
FENO50, ppb 17 (4 – 271) 
Data are presented as mean ± SD (FEV1, FVC, 
FEV1/VC, age) or as median (range; FENO50). PC20M is 
expressed as geometric mean (range).  
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Symptoms were assessed using a standardised questionnaire that covered 
symptoms and smoking habits. Symptoms listed were diurnal and nocturnal cough, 
diurnal and nocturnal wheezing, dyspnoea, chest tightness, chest pain, exercise 
trigger, humidity trigger, fumes trigger, dust trigger, pollen trigger, emotional trigger, 
rhinitis, urticaria and pyrosis. Patients underwent FENO and a methacholine 
challenge as described in the method section. The ROC curve was constructed to 
determine the value of FENO that best identified a bronchial hyperresponsiveness in 
the whole population. Logistic regression analysis was used to assess the 
relationship between the binary outcome (PC20M ≤16 mg/ml) and a set of covariates, 
individually or in combination. Covariates included FENO (log transformed), age, 
gender, FEV1, smoking and atopy. 
4.4.2 Asthma diagnosis 
Among the 174 patients referred for a methacholine challenge, 82 had a PC20M ≤16 
mg⁄ml and were thus considered as being asthmatics. The demographic and 
functional characteristics of patients according to their level of bronchial 
responsiveness towards methacholine are given in Table 13.  
Patients with positive methacholine challenge had lower baseline FEV1 (95% 
predicted vs 102% predicted, p < 0.001) and lower FEV1/FVC (p < 0.05) even if the 
average value clearly remained within the normal range. FENO was significantly 
higher in patients with positive methacholine challenge than in their negative 
counterparts (19 ppb vs. 15 ppb, p<0.05). When combining all variables into the 
logistic model, FENO (p=0.0011) and FEV1 (p<0.0001) were independent predictors 
of bronchial hyperresponsiveness to methacholine whereas age (p=0.12), gender 
(p=0.56), smoking status (p=0.56) and atopy (p=0.65) were not significant (Table 14).  
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Table 13. Demographic, functional and inflammatory characteristics for patients with and 
without asthma. 
 PC20M ≤ 16mg/ml PC20M > 16mg/ml 
N. 82 92 
Gender (M/F) 33/49  39/53  
Age, yrs 38 ± 18 * 44 ± 15  
Atopy (Y/N) 43/39 (52%) 41/51 (45%) 
Smoking (Y/N, %) 25/57 (30%) 34/58 (37%) 
PC20, mg/ml 2.44 (0.02 – 16)  
DRS FEV1 (%/µmol) 0.0033 (0.0006 – 0.4337) *** 0.0004 (0.0001 – 0.0007)  
FEV1, % predicted 95 ± 14 ** 102 ± 12  
FVC, % predicted 99 ± 14 102 ± 13  
FEV1/VC, % 82 ± 7 * 84 ± 6  
FENO, (ppb) 19 (4 - 271)* 15 (4 - 120) 
Data are presented as mean ± SD or as median (range). PC20M is expressed as geometric 
mean (range). 
 
 
Table 14. Relationship between bronchial hyperresponsiveness to 
methacholine and a set of covariates including FENO, smoking status, age, 
FEV1, atopy and gender. 
Analysis of Maximum Likelihood Estimates 
Parameter Coefficient ± SE P-value 
Intercept 3.82 ± 1.47 0.0091 
LnFENO 0.82 ± 0.25 0.0011 
Smoking -0.22 ± 0.37 0.56 
Age -0.02 ± 0.01 0.12 
FEV1 -0.06 ± 0.01 <0.0001 
LnFENO *Atopy 0.05 ± 0.11 0.65 
Gender -0.19 ± 0.33 0.56 
 
 
Lower baseline FEV1 values and higher FENO values were associated with 
PC20M≤16 mg⁄ml. We constructed a ROC curve to establish the ability of FENO to 
identify bronchial hyperresponsiveness assessed by methacholine challenge (Fig 
15).  
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We found that FENO significantly predicted PC20 ≤16 mg⁄ ml with a cut-off value of 
34 ppb. However, this FENO cut-point offers much greater specificity (95%) and 
positive predictive value (PPV) (88%) than sensitivity (35%) and negative predictive 
value (NPV) (62%). In patients with a negative methacholine challenge the upper limit 
of the 95% CI of FENO was 35 ppb. When referring to FENO normal values as 
defined by Travers et al. (149), we found that 22 patients (13%) had FENO values 
greater than the 95% confidence interval. The ability of FENO to identify airway 
hyperresponsiveness was high in those patients. Indeed 20 of the 22 patients with 
FENO values out of range according to Travers had bronchial hyperresponsiveness 
whereas this was only the case in 62 of the 152 patients in whom FENO was within 
the normal range according to Travers et al. (Odds ratio 14.5, p<0.0001). 
 
Fig 15. Receiver-operating characteristic curve 
(ROC) for the whole group determining FENO 
value which best identified the provocative 
concentration of methacholine causing a 20% fall 
in forced expiratory volume in 1 s, PC20M ≤16 
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mg⁄ml. Cut-off point: 34ppb (Specificity: 95.4%, 
Sensitivity: 35.4%, positive predictive value: 88%, 
negative predictive value: 62%, p = 0.0033. AUC = 
0.62). 
 
We constructed a ROC curve to identify which FEV1 cut-off was best related to the 
prediction of the presence of a bronchial hyperresponsiveness (Fig 16). We found 
that FEV1 significantly predicted PC20M ≤16 mg⁄ml with a cut-off value of 101%. The 
sensitivity and specificity of this threshold was 71% and 57% respectively (p=0.0001, 
AUC=0.67). 
 
Fig 16. Receiver-operating characteristic curve 
(ROC) for the whole group determining % predicted 
FEV1 value which best identified the provocative 
concentration of methacholine causing a 20% fall in 
FEV1, PC20M≤16mg⁄ml. Cut-off point: 101% 
(Specificity: 57%, Sensitivity: 71%, positive predictive 
value: 59%, negative predictive value: 68%, 
p=0.0001. AUC=0.67). 
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When combining FENO and FEV1 values to predict the presence of a bronchial 
hyperresponsiveness to methacholine, we found that the presence of both 
FENO>34ppb and FEV1≤101% predicted gave a high specificity (98.9%) but a poor 
sensitivity (24.4%) for identifying patients with positive methacholine challenge (Table 
15). 
 
Table 15. Combination of FENO and FEV1 to predict the presence of a bronchial 
hyperresponsiveness to methacholine challenge according to FENO and FEV1 cut-off value 
defined by the ROC curve. 
FENO FEV1 
 
PCM20 ≤ 16 
(n=82)  
PCM20 > 16 
(n=92) 
Frequency ratio 
A/B n % (A) N % (B) 
>34 ≤101 20 24.4 1 1.1 22.4 
>34 >101 11 13.4 2 2.2 6.2 
≤34 ≤101 39 47.6 40 43.5 1.1 
≤34 >101 12 14.6 49 53.3 0.3 
 
When FENO value >34ppb is associated with FEV1 ≤ 101% predicted, 24.4% of 
patients have bronchial hyperresponsiveness to methacholine and are thus true 
positives while there are only 1.1% of false positives. When FENO value is ≤ 34ppb 
and FEV1 >101%, 53.3% of the patients did not have bronchial hyperresponsiveness 
to methacholine and thus were true negatives while 14.6% were false negative. The 
combination of FENO and FEV1 gave a high specificity (98.9%) but a poor sensitivity 
(24.4%) for identifying patients with a positive bronchial hyperresponsiveness to 
methacholine. The Table also shows that the presence of a FENO >34ppb is more 
frequently associated with FEV1 ≤101% in patients with bronchial 
hyperresponsiveness than in patients without asthma (ratio=22.4). This ratio 
decreases if either FENO or FEV1 cut-off is not reached. A FENO value ≤34ppb 
associated with FEV1 >101% is however more frequently encountered in patients 
with negative methacholine challenge (ratio= 1/0.3 = 3.3).  
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4.4.3 Relationship between FENO and methacholine responsiveness 
On the whole population the dose-response slope (DRS) for methacholine weakly 
correlated with FENO (r=0.18; p=0.03). Among those patients positive to 
methacholine there was, however, no relationship between the magnitude of 
bronchial hyperresponsiveness (PC20M) and the level of FENO (r= -0.06, p=0.6, Fig 
17). 
 
 
Fig 17. Spearman test for patients exhibiting a 20% 
fall in FEV1 for a provocative concentration of 
methacholine ≤16 mg⁄ml. We did not find any 
correlation between FENO and provocative 
concentration of methacholine causing a 20% fall in 
FEV1 (PC20M) in those patients considered as 
asthmatics (r= -0.06, p=0.59). 
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Table 16 shows FENO according to the presence of respiratory symptoms in our 
population. Diurnal and nocturnal wheezing were associated with raised levels of 
FENO (p<0.001 and p<0.05, respectively).  
 
Table 16. FENO according to the presence of respiratory symptoms in 
a population of patients referred for asthma diagnosis. 
Symptoms                      FENO (ppb) 
 Presence of 
symptom 
Absence of symptom 
Diurnal cough 16 (4 – 271) 
N= 122 
19 (4 - 213) 
N= 52 
 
Nocturnal cough 14 (4 – 213) 
N= 62 
19 (4 – 271) 
N= 112 
 
Diurnal wheezing 20 (7 – 271)** 
N= 82 
14 (4 – 213) 
N= 92 
 
Nocturnal wheezing 20 (5 – 213) * 
N= 65 
15 (4 – 271) 
N= 119 
 
Dyspnoea 17 (5 – 213) 
N= 111 
15 (4 – 271) 
N= 63 
 
Chest tightness 16 (5 – 271) 
N= 115 
18 (4 – 142) 
N= 59 
 
Chest pain 14 (4 – 80) 
N= 46 
18 (4 – 271) 
N= 128 
 
Exercise trigger 15 (5 – 213) 
N= 99 
19 (4 – 271) 
N= 75 
 
Humidity trigger 15 (4 – 213) 
N= 64 
18 (4 – 271) 
N= 110 
 
Fumes trigger 17 (4 – 150) 
N= 87 
18 (4 – 271) 
N= 87 
 
Dust trigger 19 (5 – 142) 
N= 78 
16 (4 – 271) 
N= 96 
 
Pollen trigger 19 (5 – 118) 
N= 50 
16 (4 – 271) 
N= 124 
 
Emotional trigger 15 (5 – 213) 
N= 77 
18 (4 – 271) 
N= 97 
 
Rhinitis 17 (4 – 142) 
N= 95 
17 (4 – 271) 
N= 79 
 
Urticaria 19 (5 – 213) 
N= 48 
16 (4 – 271) 
N= 126 
 
Pyrosis 15 (4 – 142) 
N= 91 
19 (5 – 271) 
N= 83 
*p<0.05, **p<0.001. 
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Table 17 shows the proportion of symptoms according to the results of methacholine 
challenge. Patients reporting dyspnoea, diurnal and nocturnal wheezing and chest 
tightness were more likely to have a positive methacholine challenge. 
 
Table 17. Proportion of symptoms according to the results of the methacholine challenge in a 
population referred for asthma diagnosis. 
Symptoms PC20M < 16mg/ml PC20M > 16mg/ml 
Diurnal cough (Y/N, %) 54/28 (66%) 68/24 (74%)  
Nocturnal cough (Y/N, %) 30/52 (37%) 32/60 (35%)  
Diurnal wheezing (Y/N, %) 47/35 (57%)* 35/57 (38%)  
Nocturnal wheezing (Y/N, %) 46/36 (56%)** 19/73 (21%)  
Dyspnoea (Y/N, %) 60/22 (73%)** 41/51 (45%)  
Chest tightness (Y/N, %) 60/22 (73%)** 37/55 (40%)  
Chest pain (Y/N, %) 20/62 (24%) 26/66 (28%) 
Exercise trigger (Y/N, %) 53/29 (65%) 46/46 (50%) 
Humidity trigger (Y/N, %) 33/49 (40%) 31/61 (34%) 
Fumes trigger (Y/N, %) 40/42 (49%) 47/45 (51%) 
Dust trigger (Y/N, %) 42/40 (51%) 36/56 (39%) 
Pollen trigger (Y/N, %) 28/54 (34%) 22/70 (24%) 
Emotional trigger (Y/N, %) 37/45 (45%) 40/52 (43%) 
Rhinitis (Y/N, %) 49/33 (60%) 46/46 (50%) 
Urticaria (Y/N, %) 25/57 (30%) 23/69 (25%) 
Pyrosis (Y/N, %) 39/43 (48%) 52/40 (57%) 
*p<0.05, **p<0.0001.  
4.4.4 Discussion 
Our results shows that FENO>34 ppb has a high positive predictive value to identify 
bronchial hyperresponsiveness to methacholine in patients who had respiratory 
symptoms suggestive for asthma and in whom the respiratory physician had no 
argument for airway flow variability either because baseline calibre was considered to 
be normal or because bronchodilation to inhaled β2-agonist was weak (184). 
However, the sensitivity of 34 ppb cut-off is poor and FENO values below this 
threshold clearly do not rule out bronchial hyperresponsiveness. Furthermore, we 
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found that, among a list of respiratory symptoms, wheezing was the symptom that 
was the most convincingly associated with raised FENO. Airway 
hyperresponsiveness and airway inflammation are acknowledged to be key but 
largely independent features of asthma (2;76). Many asthmatics are routinely 
diagnosed based on the association between chronic respiratory symptoms and the 
demonstration of airway variability. Reversibility to inhaled β2-agonist and 
methacholine⁄histamine bronchial challenge are the most common ways used to 
confirm suspected asthma. In those patients with normal baseline lung function it was 
shown that a bronchodilation test and peak expiratory flow rate variability perform 
rather weakly to ascertain the diagnosis (70;71). FENO has been advocated as a 
useful tool to make asthma diagnosis in steroid-naïve patients with respiratory 
symptoms (70;73). The population selected in our study is slightly different from 
those described in previous studies in that only patients in whom asthma diagnosis 
remains uncertain after reversibility testing and ⁄ or baseline spirometry were sent to 
our routine function laboratory for a methacholine challenge. Furthermore, it is of 
interest to note that the proportion of atopic patients was rather low (50%) and the 
proportion of active smokers rather high (35%) for a population of 
mild to moderate steroid-naive asthmatics. Dupont (73) and Smith (70) excluded 
smokers and the series of Smith et al. (70) included 76% of atopic subjects whereas 
their proportion was not mentioned in the study of Dupont et al. The relatively weak 
proportion of atopy and the presence of smokers certainly explain why the average 
FENO value in our series is clearly lower than that reported in patients attending an 
asthma clinic (150;166). Our results show that bronchial NO may predict 
methacholine hyperresponsiveness reflected by PC20M ≤16 mg⁄ ml with FENO cut-
off >34 ppb yielding 95% specificity and 88% positive predictive value. Our data show 
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that 20% with confirmed asthma had FENO value >34 ppb. In contrast to the 
specificity, sensitivity of 34 ppb threshold is poor and a value below this threshold 
clearly does not exclude the presence of bronchial hyperresponsiveness. It is 
important to realise that FENO and PC20M values are largely independent variables. 
Indeed the correlation between DRS (dose-response slope) for methacholine and 
FENO is weak for the whole population and we did not find any significant 
relationship between FENO and PC20M in those patients diagnosed as asthmatics. 
This contrasts with what we have recently found concerning the relationship between 
FENO and sputum eosinophils in a large heterogeneous series of asthmatics 
encountered in daily practice (166). 
The relationship between FENO and airway hyperresponsiveness is controversial 
and conflicting results have been published (52;69;70;185-188). Compared with our 
patients, the studies showing a more convincing relationship between FENO and 
bronchial hyperresponsiveness included a significantly higher proportion of atopic 
patients. We found, however, by a multiple regression analysis that atopy, in contrast 
to FENO, was not an independent predictor of bronchial hyperresponsiveness. On 
the other hand, Smith et al. (70) used hypertonic saline, an indirect stimulus, to 
measure bronchial responsiveness. It is recognised that airway inflammation is better 
related to indirect than to direct bronchial hyperresponsiveness (189). Although 
FENO and PC20M reflect different dimensions in asthma, it does not exclude 
functional relationship between the two variables. It is admitted that part of the 
bronchial hyperresponsiveness in asthma is linked to an airway eosinophilic 
inflammation that can be attenuated by corticosteroids (190). 
Furthermore, nitric oxide may itself contribute to bronchial hyperresponsiveness by 
increasing airway oedema as it is a potent vasodilator responsible for plasma 
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exudation from bronchial vessels (191) and the transformation of NO in peroxynitrite 
was shown to induce airway hyperresponsiveness in guinea pigs (192). This may 
explain the good specificity of FENO to detect methacholine responsiveness even if it 
is not perfect, as increased FENO may be observed in other pathological conditions 
such as eosinophilic bronchitis (74) where bronchial hyperresponsiveness is absent. 
It is also interesting to note that FENO values outside the normal range as defined by 
Travers et al. (149), whilst being rather rare in our series (13%), carry a high odds 
ratio (14.5) in favor of bronchial hyperresponsiveness. This observation highlights the 
fact that consistent airway inflammation may be a determinant factor of bronchial 
hyperresponsiveness. The multiple logistic regression analysis confirmed the effect of 
baseline airway caliber as a strong independent predictor of the presence of 
bronchial hyperresponsiveness to methacholine. Some studies have shown a 
correlation between FEV1 and bronchial hyperresponsiveness (187;193;194). This 
suggests that airway geometric factors are involved in the mechanisms of bronchial 
hyperresponsiveness in asthma. Beyond geometry there is also solid argument to 
support the role of bronchial smooth muscle dysfunction in determining 
hyperresponsiveness to a direct constricting agent (195). Although atopy was shown 
to correlate with bronchial hyperresponsiveness in epidemiological and clinical 
studies (196), our data suggest that its influence may be mediated by an increase in 
airway inflammation as atopic patients clearly exhibited higher FENO than non-atopic 
(19ppb vs. 15ppb, p <0.01). We therefore believe that it is not atopy per se that 
matters in determining bronchial hyperresponsiveness but rather the fact that atopy 
may favour airway inflammation in the event sensitised patients are exposed to a 
relevant allergen. It is important to emphasise that smoking status did not impact on 
bronchial hyperresponsiveness to methacholine in our study. Smoking has been 
113 
 
shown to induce airway hyperresponsiveness in the general population (197). Our 
data show that smoking may be less critical when considering selected patients 
based on the presence of chronic respiratory symptoms. There are only limited data 
on the precise relationship between the type of symptoms and airway inflammation. 
In our study diurnal and nocturnal wheezing was associated with proximal airway 
inflammation as reflected by raised levels of FENO. Leuppi et al. reported the same 
observation in a population of children (198). Although it is admitted that asthma may 
sometimes be revealed by isolated coughing (199), our data show that coughing is 
generally poorly related to methacholine hyperresponsiveness and to FENO. As 
compared with FENO, bronchial hyperresponsiveness to methacholine is associated 
with a broader spectrum of symptoms including not only wheezing but also dyspnoea 
and chest tightness that are likely to better reflect airflow limitation than wheezing 
alone. 
The purpose of our study was not to look at asthma phenotypes but rather to validate 
an inflammometer as a diagnostic tool for the currently accepted definition of asthma 
according to GINA. A key issue is to know whether or not those patients with chronic 
respiratory symptoms and high FENO are better responsive to inhaled corticoids 
irrespective of their level of bronchial hyperresponsiveness and their ‘asthma’ label. 
This has been suggested by a pilot monocentric study (200) but has yet to be 
confirmed in a study conducted on a larger scale. 
4.4.5 Conclusion 
We conclude that FENO measurement may be useful to the clinician in diagnosing 
asthma in patients with chronic respiratory symptoms in whom the bronchodilating 
test failed to demonstrate reversibility or was not indicated. However, the poor 
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sensitivity of FENO to detect bronchial hyperresponsiveness should prompt the 
clinician to ask for a methacholine challenge when asthma is suspected based on 
clinical history in case of FENO<34 ppb (Fig 18). According to our data, application of 
the algorithm proposed in Fig 18 could reduce methacholine challenges performed in 
a routine pulmonary function laboratory by 20%. This is significant as methacholine 
challenge is time consuming and uncomfortable to the patients. 
 
 
Fig 18. Proposed algorithm for asthma diagnosis. Values <34 ppb 
should prompt the clinician to ask for a methacholine challenge when 
asthma is suspected based on clinical history. The application of the 
proposed algorithm could reduce by 20% the methacholine 
challenges performed in a routine lung function laboratory. 
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4.5 Value of measuring blood and sputum eosinophil cell counts  
It is now accepted that eosinophilic asthma, defined as a sputum eosinophil count of 
2–3% or higher, represents slightly less than half of the asthmatic population 
(13;43;124;128). In asthma, sputum eosinophil count correlates with blood eosinophil 
count (128;163-165) and blood eosinophil count is considered as a good surrogate 
marker for sputum eosinophil count (over 2–3% with a cut-off of 220 cells per mm³ or 
3%) (128;140). However, the sensitivity and specificity of blood eosinophils to predict 
a sputum eosinophil proportion of ≥3% are <80%, and some patients show 
discordance between local and systemic inflammation. 
In this study, we sought to determine whether looking at blood and sputum 
eosinophilic inflammation might help in our understanding of asthma severity. We first 
retrospectively investigated the demographic, functional and symptomatic features of 
508 asthmatics recruited from the University Asthma Clinic of Liege between the 1st 
October 2005 and 27th June 2011 and classified them according to systemic and 
local eosinophilic inflammation, then prospectively validated the relationship between 
asthma control and eosinophilic inflammation in a new cohort of 250 patients well-
matched to our retrospective cohort with respect to demographic, functional and 
treatment characteristics.  
The patients came from the routine practice to University Hospital, Liege, and were 
recruited by two clinicians involved in asthma. Inclusion criteria were any patients 
with asthma aged ≥18 years who agreed to undergo detailed investigation at the 
asthma clinic. The visits were not part of an asthma trial. All the patients who had a 
successful sputum induction were included in the study. Their demographic and 
functional characteristics are summarised in Tables 18 and 19. 
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Table 18.  Demographic, control and treatment characteristics for the whole population. 
Characteristics Retrospective population Prospective population 
N. 508 250 
Gender (M/F) 201/307 99/151  
Age, yrs 52 (19-88) 50 (16-85) 
Age of onset 
   <12 
   12-40 
   ≥40 
 
24% 
37% 
39% 
 
22% 
36% 
42% 
Height, cm 167 ± 9 168 ± 9 
Weight, kg 74 ± 16 73 ± 17 
Atopy (Y/N, %) 296/212 (58%) 148/102 (59%) 
Current Smoker (n)  
                 (pack-yr) 
Ex-smokers (n)  
                 (pack-yr) 
101 (20%)     
22 (0.5-60) 
99 (19%)   
15 (0.5-90) 
55 (22%)     
25 (2-60) 
38 (15%) 
17 (0.5-63) 
Bronchiectasis (%)  19% (n=174) 17% 
Gastro-oesophageal reflux (%) 79% 71%* 
Nasal polyposis 
Sinusitis 
22% (n=273) 
42% (n=273) 
27% 
41% 
Rhinitis 58% 56% 
Exacerbations (/patient/yr) 0.68 ± 1.50 (n=428) 0.86 ± 2.02  (n=237) 
LABA, Y (%) 319 (63%) 141 (56%) 
LTRA, Y (%) 93 (18%) 50 (20%) 
Theophylline, Y (%) 16 (3%) 11 (4%) 
ICS therapy, Y (%) 
     Steroid naïve 
     Low dose ICS 
     Moderate dose ICS 
     High dose ICS 
 
153 (30.5%) 
73 (14%) 
138 (27.5%) 
144 (28%) 
 
82 (33%) 
35 (14%) 
63 (25%) 
70 (28%) 
Oral corticosteroids, Y (%) 32 (6%) 25 (10%) 
Data are presented as mean ± SD or median (range). Y: yes. Exacerbations were evaluated 
during the year prior to the visit. *p<0.05.  
 
 
Exacerbation in the previous year was defined by a course of oral corticoids for ≥3 
days for a case of worsening asthma. Nasal polyps and sinusitis was diagnosed by 
an ear, nose and throat physician, either by endoscopy or sinus computed 
tomography. Gastro-oesophageal reflux was diagnosed either by symptoms of 
pyrosis at history taking or by the presence of oesophagitis demonstrated by 
gastroscopy. 
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Table 19. Functional and inflammatory characteristics for the whole population 
Characteristics Retrospective population Prospective population 
FEV1, % predicted 84 ± 19 82 ± 21 
FEV1/FVC, % 73 ± 11 71 ± 15* 
PC20M, mg/ml 3.20 (0.025-16) 2.92 (0.05-16) 
Reversibility, % 11 ± 14 9 ± 10 
ACQ 2.01 ± 1.38 2.00 ± 1.25 
AQLQ 4.61 ± 1.35 4.46 ± 1.39 
Blood eosinophil count, /mm³ 230 (0-3220) 188 (0-1133)* 
FENO50 27 (0-247) 25 (4-348) 
Sputum eosinophils, % 2 (0-94) 2.8 (0-90) 
Sputum neutrophils, % 45 (0-100) 49 (0-100) 
Data are presented as mean ± SD or median (range). PC20M is expressed as 
geometric mean (range). *p<0.05. 
 
 
To validate the results of the retrospective analysis of the link between asthma 
control and eosinophilic inflammation we conducted a prospective study. Power 
calculations indicated a required total sample size of 250 subjects to confirm a 
change in ACQ score ≥0.5 between non-eosinophilic asthmatics and patients 
exhibiting diffuse eosinophilic inflammation, with a power of 80%. A new cohort of 
250 consecutive patients was thus recruited from routine practice between 30th June 
2011 and 12th January 2013. None of these patients had been included in the 
retrospective cohort. Their demographic, functional and treatment characteristics 
were similar to the retrospective population (Tables 18 and 19). Exacerbation rate for 
the prospective population was measured through a telephone call over a period of 
12 months following the visit to the asthma clinic, during which treatment was initiated 
or adjusted according to asthma control, lung function and inflammatory markers at 
the discretion of the clinician. 13 patients were lost to follow-up, and in the 17 
patients in whom the observation period was <1 year, we calculated the annualised 
exacerbation rate. We used blood eosinophil count and sputum eosinophil 
percentage to subdivide our asthmatic population into four groups. The chosen blood 
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(≥400 cells per mm3) (10) and sputum (≥3%) threshold values were considered as 
the limit of abnormality by our routine laboratory. The demographic, functional and 
inflammatory characteristics of the retrospective cohort of asthmatics, classified 
according to their blood and sputum eosinophil counts are described in Table 20-22.  
 
Table 20. Retrospective cohort: demographic and treatment characteristics of asthmatics 
(n=508) according to blood and sputum eosinophil count. 
 Blood eos <400/µl 
Sputum eos <3% 
Blood eos<400/µl 
Sputum eos ≥3% 
Blood eos≥400/µl 
Sputum eos <3% 
Blood eos ≥400/µl 
Sputum eos ≥3% 
N 249 (49%) 128 (25%) 34 (7%) 97 (19%) 
Gender (M/F) 78/171 54/74* 16/18 53/44*** 
Age, yrs 52 (21-86) 53 (21-88) 51 (21-85) 51 (19-86) 
Age of onset 
   <12 
   12-40 
   ≥ 40 
 
22.6% 
34.5% 
42.9% 
 
27.6% 
36.2% 
36.2% 
 
26.5% 
32.3% 
41.2% 
 
23.3% 
45.6% 
31.1% 
Height, cm 166±9 168±9 169±9 169±9 
Weight, kg 73±16 74±15 76±17 75±17 
BMI (kg/m²) 26.3±5 26.4±5 26.3±4.8 26.4±5.3 
Atopy (Y/N, %) 126/123 (51%) 82/46 (64%)* 22/12 (65%) 66/31 (68%)** 
Current smoker 54 (22%) 29 (23%) 6 (18%) 12 (12%)* 
Bronchiectasis 
(%) (n=174) 
19% 13% 17% 26% 
Gastro-
oesophageal 
reflux (%) 
77% 81% 86% 77% 
Nasal Polyposis 
Sinusitis 
(n=273) 
9% 
34% 
25%*** 
38% 
37%*** 
42% 
43%*** 
61%*** 
Rhinitis 53% 59% 72% 65% 
Exacerbations 
(/patient/yr) 
0.42 ± 0.9 0.93 ± 2.72* 0.59 ± 0.98 1.5 ± 2.5*** 
ICS therapy 
   Steroid naïve 
   Low dose 
   Moderate  
   High dose 
 
82 (33%) 
30 (12%) 
70 (28%) 
67 (27%) 
 
31 (24%) 
20 (16%) 
37 (29%) 
40 (31%)* 
 
9 (26.5%) 
5 (15%) 
11 (32%) 
9 (26.5%) 
 
31 (32%) 
18 (18%) 
20 (21%) 
28 (29%) 
*p<0.05, **p<0.01, ***p<0.001. Data are presented as mean ± SD or median (range). Column 
of blood eosinophil count <400/µl and sputum eosinophil count <3% is used as the 
comparator. 
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Table 21. Retrospective cohort. Functional characteristics, asthma control and quality of life 
of asthmatics (n=508) according to blood and sputum eosinophil count. 
 Blood eos <400/µl 
Sputum eos <3% 
Blood eos<400/µl 
Sputum eos ≥3% 
Blood eos≥400/µl 
Sputum eos <3% 
Blood eos ≥400/µl 
Sputum eos ≥3% 
FEV1, % predicted 87±19 83±20* 84±23 75±19*** 
FEV1/FVC, % 75±10 72±9* 77±10 71±10*** 
TLC (% predicted) 101±16 101±20 92±21 103±15 
FRC (% pred) 109±29 108±20 97±30 101±18 
KCO (% pred) 89±19 92±20 99±14** 94±26* 
PC20, mg/ml 3.99 (0.05-16) 2.32 (0.025-16)* 4.53 (0.05-16) 1.49 (0.05-16)** 
Reversibility, % 8 ± 9 13 ± 14* 9 ± 12 17 ± 16*** 
ACQ 
     <0.75 (n) 
     0.75-1.5 (n) 
     >1.5 (n) 
1.88±1.39 
58 (23%) 
45 (18%) 
146 (59%) 
1.87±1.19 
26 (20.5%) 
30 (23.5%) 
72 (56%) 
1.98±1.5 
7 (21%) 
10 (29%) 
17 (50%) 
2.54±1.45*** 
10 (10.5%) 
15 (15.5%) 
72 (74%)* 
AQLQ 4.67±1.36 4.84±1.3 4.47±1.26 4.3±1.4* 
*p<0.05, **p<0.01, ***p<0.001. Data are presented as mean ± SD or median (range); PC20 is 
expressed as geometric mean (range). Column of blood eosinophil count <400/µl and 
sputum eosinophil count <3% is used as the comparator. 
 
 
Table 22. Retrospective cohort. Inflammatory characteristics of asthmatics (n=508) 
according to blood and sputum eosinophil count. 
 Blood eos 
<400/µl 
Sputum eos <3% 
Blood eos<400/µl 
Sputum eos ≥3% 
Blood eos≥400/µl 
Sputum eos <3% 
Blood eos 
≥400/µl 
Sputum eos ≥3% 
IgE, kU/l 87 (1-7338) 211 (3-6785)*** 180 (13-2329)* 225 (1-17183)*** 
Blood eosinophils, % 1.7 (0-5.4) 3.2 (0-7)*** 6 (0.3 – 15)*** 8 (0.4 – 30)*** 
Blood eosinophils, /mm³ 140 (0-380) 250 (0-390)*** 490 (400-1220)*** 590 (400-
3220)*** 
Blood neutrophils, % 59 (27-82) 57 (34-91) 57 (41-76) 52 (32-67)*** 
Blood neutrophils, /mm³ 4180 (76-11080) 4370 (2290-15410) 5040 (1760-10010) 3965 (1820-8670) 
Sputum eosinophils, % 0.3 (0-2.9) 9 (3-79)*** 0.6 (0-2.8) 26 (3.2-94)*** 
Sputum eosinophils, 
/mm³ 
2.7 (0 – 1020) 70 (6-5226)*** 4.8 (0-1796) 287 (5-33375)*** 
Sputum neutrophils, % 58 (0-100) 39 (0-90)*** 57 (0.2-99) 30 (0.2 -91)*** 
Sputum neutrophils, 
/mm³ 
422 (0 – 73440) 334 (1-9588) 560 (14 -160974) 259 (1-15441) 
Fibrinogen (g/l) 3.2 (1.9-10) 3 (2-6) 3.3 (2.6-5) 3.4 (2.2-7) 
CRP (mg/l) 1.7 (0.2-10) 2 (0.2-14) 1.4 (0.5-4) 1.6 (0.2-13) 
FENO, ppb 17 (0-192) 37 (2-222)*** 32 (5-93)** 77 (11-247)*** 
*p<0.05, **p<0.01, ***p<0.001. Data are presented as mean ± SD or median (range); Column 
of blood eosinophil count <400/µl and sputum eosinophil count <3% is used as the 
comparator. 
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The patients without evidence of eosinophilic inflammation represented the largest 
group, accounting for 49% of the cohort. Those patients with selective airway 
eosinophilic inflammation came second, accounting for 25% of the patients, whereas 
those exhibiting the reverse pattern were much less numerous, only representing 7%. 
Patients combining systemic and airway eosinophilic inflammation account for 19% of 
the patients. The inhaled corticoids treatment regimen was similar between 
subgroups (Table 20). Compared with non-eosinophilic asthmatics, the 
characteristics of patients exhibiting isolated sputum eosinophilia were a higher 
proportion of males and atopic subjects, higher total serum IgE levels, lower FEV1 
and FEV1/forced vital capacity ratio, and higher bronchial hyperresponsiveness and 
reversibility to β2-agonists (Fig 19, and Tables 21 and 22). As for patients with high 
levels of blood eosinophils without sputum eosinophilia, they had a higher total serum 
IgE compared with noneosinophilic asthmatics (Fig 19 and Table 22). The presence 
of both local and systemic eosinophilic inflammation was strikingly more frequent in 
males, and associated with the greatest lung function impairment, and the lowest 
asthma control (mean±SEM ACQ score 2.54±1.45 versus 1.88±1.39; mean 
difference 0.66, 95% CI  -0.99– -0.32 (p=0.0001)) (Fig 19 and 20) and quality of life 
(Table 21).  
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Fig 19. Demographic, functional and inflammatory characteristics of patients 
according to their level of local and systemic eosinophil count. 
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Fig 20. Asthma control questionnaire (ACQ) according to the level of blood and sputum 
eosinophil count. The presence of both local and systemic eosinophilic inflammation was 
associated with lower asthma control. Group 1: blood eosinophil count <400/µl and sputum 
eosinophil count <3%. Group 4: blood eosinophil count ≥400/µl and sputum eosinophil count 
≥3%.  Panel a: retrospective population (n=508). Panel b: prospective population (n=250). 
 
 
They also had the highest FENO while those with eosinophilia in only one 
compartment had similar, intermediate FENO. Non-eosinophilic asthmatics had the 
lowest FENO, comparable to that found in healthy subjects (Fig 21 and Table 22). 
 
 
Fig 21. FENO levels in patients classified according to the presence 
and/or absence of blood and sputum eosinophilia. Patients exhibiting 
both local and systemic inflammation had the highest level of FENO in 
their exhaled air (n=508). Presence of uncontrolled eosinophilic 
inflammation either at local or systemic level was associated with 
intermediate levels of FENO. The group of asthmatics showing no 
increase in eosinophilic inflammation had the lowest level of FENO. 
Group 1: blood eosinophil count <400/µl and sputum eosinophil count 
<3%; Group 2: blood eosinophil count <400/µl and sputum eosinophil 
count ≥3%; Group 3: blood eosinophil count ≥400/µl and sputum 
eosinophil count <3%; Group 4: blood eosinophil count ≥400/µl and 
sputum eosinophil count ≥3%.  
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Patients with increased sputum eosinophilia reported greater numbers of severe 
exacerbations in the previous year, and this was particularly the case for those 
displaying concordant systemic and airway eosinophilia (Table 20). Likewise, the 
proportion of sinusitis and nasal polyps was clearly higher in eosinophilic asthmatics 
however there was no difference regarding gastro-oesophageal reflux (Table 20). 
In patients treated with high doses of inhaled corticosteroids (n=144), the proportions 
of the different subgroups were similar to those found in the whole cohort, and the 
subgroup exhibiting both bronchial and systemic eosinophilic inflammation had the 
highest exacerbation rate and the poorest lung function (Table 23). 
 
Table 23. Demographic, functional and inflammatory characteristics of patients receiving 
high doses corticosteroids in the retrospective cohort (n=144).  
 Blood eos <400/µl 
Sputum eos <3% 
Blood eos<400/µl 
Sputum eos ≥3% 
Blood eos≥400/µl 
Sputum eos <3% 
Blood eos ≥400/µl 
Sputum eos ≥3% 
N 67 (47%) 40 (28%)  9 (6%)  28 (19%)  
Gender (M/F) 20/47 16/24 5/4 15/13 
Age, yrs 52 (21 – 86) 59 (26 – 88) 62 (44 – 85) 52 (29 – 86) 
Age of onset,% 
       <12 
       12-40 
       ≥ 40 
 
25 
33 
42 
 
35 
30 
35 
 
0 
50 
50 
 
30 
40 
30 
Exacerbations 
(/patient/yr) 
0.76 ± 1.06 0.95 ± 1.29 1.25 ± 1.17 3.52 ± 5.00*** 
FEV1, % pred 77 ± 17 77 ± 20 71 ± 28 65 ± 18** 
FEV1/FVC, % 73 ± 11 68 ± 13 70 ± 11 64 ± 9** 
ACQ 2.57 ± 1.96 1.97 ± 1.25 3.19 ± 1.79 3.18 ± 1.38 
AQLQ 4.11 ± 1.39 4.52 ± 1.40 3.59 ± 1.47 3.50 ± 1.31 
FENO50 14 (4-114) 30 (8 – 119)*** 10 (5 – 58) 55 (11 – 139)*** 
Blood 
eosinophil 
count, /mm³ 
160 (10 – 350) 225 (0 -390)*** 465 (400 – 
1030)*** 
615 (400 – 
3220)*** 
Sputum 
eosinophil 
count, % 
0.25 (0 – 2.6) 8.4 (3 – 52.2)*** 0.4 (0 – 2.7) 22.3 (3.6 – 
94.4)*** 
*p<0.05, **p<0.01,***p<0.001. Column of blood eosinophil count <400/µl and sputum 
eosinophil count <3% is used as the comparator. 
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In order to validate the relationship between poor asthma control and comprehensive 
eosinophilic inflammation, we prospectively recruited a population of 250 asthmatics 
whose demographic, functional and inflammatory characteristics were similar to our 
retrospective cohort (Tables 20 and 21). In this population, we found similar 
proportions of patients in the different subgroups (47% were patients without 
evidence of eosinophilic inflammation, 32% exhibited isolated sputum eosinophilia, 
4% had isolated systemic eosinophilia and 17% combined systemic and airway 
eosinophilia) and confirmed that patients with both systemic and airway eosinophilic 
inflammation had poorer asthma control compared with non-eosinophilic asthma 
(mean±SEM ACQ score 2.23±1.40 versus 1.79±1.12; mean difference 0.44, 95%CI 
0.007–0.89 (p<0.05)) (Fig 16). In the prospective cohort, patients exhibiting diffuse 
eosinophilic inflammation had a higher number of exacerbations in the year prior to 
the visit to the asthma clinic (mean±SD 1.11±1.65, n=41) than non-eosinophilic 
patients (mean±SD 0.77±2.55, n=111) (p<0.05). Interestingly, for the whole cohort, 
the exacerbation rate over the 12months following the asthma clinic visit decreased 
compared with that occurring in the previous year (mean 0.86±2.02 (95% CI 0.61–
1.12) versus mean 0.50±1.18 (95% CI 0.35–0.65) after) (p=0.015). Moreover, in the 
year following the visit to the asthma clinic, the number of exacerbations was 
significantly higher in patients advised to take high-dose ICS (mean±SD 1.06±1.63, 
n=93) than in those advised to take low (mean±SD 0.17±0.62, n=58) or moderate 
(mean±SD 0.15±0.40, n=55) doses of ICS or not to take ICS at all (0±0, n=31) 
(p<0.0001). 
When pooling both the retrospective and the prospective cohort (n=758), there was a 
weak but significant relationship between ACQ and sputum eosinophil count (r=0.16, 
p<0.0001) but not between blood eosinophils and ACQ (r=0.02, p=0.57) (Fig 22). 
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Fig 22. Correlation between ACQ and sputum eosinophil count (upper 
figure) and blood eosinophil count (lower figure) when combining the 
prospective and retrospective cohort (n=758). Asthma is considered 
uncontrolled if ACQ >1.5 (blue line). 
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The original finding of this study is that patients exhibiting both local and systemic 
eosinophilic inflammation had more severe asthma reflected by lower baseline lung 
function, higher bronchial responsiveness to methacholine, poorer asthma control 
and quality of life, and a greater number of exacerbations in the previous year. This 
suggests that the global magnitude of eosinophilic inflammation is a significant factor 
in disease severity. Another new finding of this study is that it provides figures on the 
proportion of asthmatics classified according to the site of eosinophilic inflammation. 
Overall, asthmatics without any sign of eosinophilic inflammation account for almost 
half of the patients while one-quarter to one-third had selective airway eosinophilia. 
Patients with systemic and airway eosinophilic inflammation represent one-fifth of the 
patients, while those with isolated systemic eosinophilic inflammation are rather rare. 
These proportions are found irrespective of asthma treatment received including high 
doses of inhaled corticoids. We believe our new classification based on eosinophilic 
inflammation is pertinent to the clinician and is in line with the need to phenotype 
severe asthmatics as advocated by the recent ERS/ATS guidelines (93). 
As mentioned, the link between eosinophils and asthma severity has been 
extensively debated. The first attempts to investigate this relationship were based on 
sampling BAL or biopsies during bronchoscopy. The invasive nature of the procedure 
has obviously limited the number of subjects studied, which may have led to 
contrasting results because of interindividual patient variability. Being less invasive, 
the technique of induced sputum has considerably widened the series of patients 
investigated and has been key to the emergence of recognition of several 
inflammatory asthma phenotypes. Previous studies found higher levels of sputum 
eosinophil counts in uncontrolled asthmatics (50;142). Another study showed that 
patients with high blood eosinophilia (>250 cells per mm³) had lower FEV1 values and 
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worse asthma control than those with normal blood eosinophil counts (201). 
Recently, Volbeda et al. (85) have shown that patients with uncontrolled asthma 
exhibit higher eosinophil numbers in peripheral blood and a trend for a higher 
eosinophil count in induced sputum, but they did not provide detailed analysis on the 
discordance between blood and airway eosinophilia. Here, in our retrospective 
cohort, we found that patients exhibiting eosinophilic inflammation both in blood and 
sputum had more severe asthma and poorer asthma control than noneosinophilic 
asthmatics, a finding that was validated in our prospective cohort. Our data show 
that isolated sputum eosinophilic inflammation is associated with impaired airway 
calibre and increased airway hyperresponsiveness compared with non-eosinophilic 
asthmatics, while those combining both systemic and eosinophilic had further 
functional impairment, which is likely to partly contribute to worse asthma control and 
quality of life. Three-quarters of this group had an ACQ score >1.5 while only 10% 
had well-controlled asthma with an ACQ score <0.75. However, having an 
eosinophilic trait, whichever the compartment, is associated with a slightly raised 
proportion of atopy and higher serum IgE levels. 
It is important to note that patients in the group with blood and sputum eosinophilia 
had much higher sputum eosinophil counts compared with those with sputum 
eosinophilia alone. Beyond the categorical analysis, the extent of eosinophilic airway 
infiltration has to be taken into consideration. Our finding reinforces the role of airway 
eosinophilia in the loss of asthma control previously suggested on a smaller sample 
of patients (40). The intensity of blood eosinophilic inflammation in patients exhibiting 
diffuse eosinophilic inflammation was comparable to that of asthmatics with isolated 
blood eosinophilia, a group that was less severe. Moreover, there was no correlation 
between ACQ and blood eosinophil counts. This suggests that circulating eosinophils 
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by themselves are not direct actors of asthma severity but are important in providing 
a pool of cells that can be attracted in the airways. 
Approximately 70% of patients exhibiting diffuse eosinophilic inflammation were 
receiving maintenance treatment with inhaled corticoids. While we could speculate 
that raising the dose of ICS in those receiving low to moderate doses would have 
resulted in a reduction of eosinophilic inflammation, it is noteworthy that 30% of the 
ICS treated patients were already receiving high doses. This highlights the relative 
resistance to corticoids in some patients and the need for complementary treatment 
to target eosinophils. Among the patients receiving high doses of inhaled corticoids, 
53% exhibited either blood or sputum eosinophilia that could make them potential 
candidates for treatment with anti-interleukin-5 (10;11). A recent study has shown 
that omalizumab is more efficient in reducing exacerbation when patients express a 
Th2 profile including high blood eosinophil counts or FENO levels (98). Of course, as 
our study was a field study, we cannot rule out poor compliance in some patients, 
making the interpretation of corticoid resistance in these asthmatics difficult. 
Here, we deliberately chose to classify our patients according to pre-specified criteria, 
which were blood and sputum eosinophils. Our approach was therefore different from 
that used in hierarchical unsupervised cluster analysis. We do not deny the great 
interest of this type of cluster analysis in the emergence of clinical asthma 
phenotypes, but we believe that classifying asthmatics according to their eosinophilic 
profile is useful because sputum and blood eosinophils are good biomarkers to target 
treatment and predict response to corticoids or biologicals directed towards Th2 
cytokines (202;203). Furthermore, it has recently been advocated that sputum 
eosinophils may be a valuable outcome in asthma drug trials (202). How our asthma 
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groups may fit with those found by others after cluster analysis remains to be 
determined (6;204;205). There are some similarities coming out of both approaches 
regarding the link between eosinophilia and gender. While females are the dominant 
sex among adult asthmatics, our data show that this is mainly accounted for by the 
non-eosinophilic group even if females remained the predominant sex in those with 
isolated airway eosinophilic asthma. It is noteworthy that the proportion of males was 
significantly higher in those patients with an eosinophilic trait compared with their 
non-eosinophilic counterparts and, in our study, it is striking that males become the 
predominant sex in the case of diffuse eosinophilic inflammation. This is likely to 
reflect the different hormonal status and its effect on eosinophil biology. Few studies 
have evaluated the relationship between eosinophils and sex hormones. It seems 
that β-oestradiol significantly enhances eosinophil adhesion to human mucosal 
microvascular endothelial cells and their degranulation (206;207). 
By contrast, our data do not point to any particular link between obesity and non-
eosinophilic asthma, as BMI was similar in all our groups of patients. 
Of interest is the fact that classic systemic inflammatory markers such as fibrinogen 
and C-reactive protein do not link at all with the severity of eosinophilic inflammation, 
a phenomenon that contrasts with what is usually seen in airway diseases exhibiting 
neutrophilic inflammation (208;209). 
Approximately one-third of asthmatics exhibit dissociation between airway and 
systemic inflammation. The reasons why there may be discordant eosinophilic 
inflammation between blood and sputum remains unclear. In case of intense airway 
eosinophilic inflammation without blood eosinophilia, we could speculate about a 
massive local attraction due to the release of chemotactic agents without heavy 
stimulation of bone marrow. In patients with high blood eosinophil count and low 
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sputum eosinophils, there could be a lack of transendothelial migration of eosinophils 
due to altered receptor expression or receptor down-regulation. An alternative 
explanation would be that the airway eosinophilic inflammation is masked by 
macrophage phagocytosis of eosinophils (134). This could explain the intermittent 
eosinophilic phenotype (140) and the intermediate FENO we found in this subgroup, 
as FENO is a good surrogate marker for sputum eosinophilia (166). 
However simply looking at cell counts does not provide a complete picture of the cell 
role in pathophysiology (210). Eosinophil activation by primary lysis results in the 
spilling of toxic protein-releasing free eosinophil granules in the bronchial tissue 
(85;211). Lysis of tissue-dwelling eosinophils may partly explain lack of sputum 
eosinophilia in patients who nevertheless suffer from eosinophilic asthma (212). 
Asthma-relevant stimuli, including allergens and microbial factors, produce prompt 
eosinophil lysis. Primary lysis of eosinophils in the airways is likely to be an essential 
contributor to the intensity of airway eosinophilic inflammation and thereby asthma 
control. Therefore the relationship with asthma control could have been stronger if we 
had looked at eosinophil activation.  
Even if eosinophilic inflammation appears to be important in driving asthma severity, 
it has to be kept in mind that half of asthmatics did not display any sign of 
eosinophilic inflammation, among whom 59% remained poorly controlled. Of course, 
for those already receiving inhaled corticoids, it could be argued that some of them 
may have been eosinophilic prior to initiation of ICS treatment. The current literature 
suggests, however, that initiating or increasing the dose of inhaled corticoids in those 
non-eosinophilic patients is probably useless for improving asthma control (87). This 
highlights the need to develop and test new drugs in this asthma phenotype. 
Clarithromycin was shown to slightly improve quality of life in refractory neutrophilic 
131 
 
asthmatics and a recent study suggests that azithromycin may reduce exacerbation 
in patients with low blood eosinophil counts (25). 
The main limitation of our study is the single time-point measurement that does not 
take into account the possible fluctuation of the patients from one group to another 
over time. Indeed, some patients were shown to be intermittently eosinophilic in their 
sputum, which may cause bias when dealing with a single measurement. However, 
we believe that looking at the relationship between ACQ score and sputum 
eosinophils based on one single evaluation remains valid, as ACQ score reflects 
disease control on a short time period (1 week), a period over which sputum 
eosinophil count was found to be reproducible (213). 
Exacerbation rate, which was clearly higher in the group with combined eosinophilic 
inflammation, must be considered cautiously as it was based on history taking, and it 
is not always easy to disentangle what was justified by genuine asthma worsening or 
by a flare-up of sinusitis with coughing. Nevertheless, the fact that the prospective 
cohort confirmed the proportion of eosinophilic subgroups and the exacerbation rates 
found in the retrospective cohort is quite reassuring of the validity of our 
classification. Of interest also is the fact that exacerbation rate decreased on average 
by 42% in the year after the visit to our asthma clinic, suggesting that what the 
clinician decided based on a comprehensive investigation has had an impact on 
long-term asthma control. Reassuring is the fact those patients for whom the clinician 
did not feel the need to prescribe an ICS after their asthma clinic visit did not report 
any exacerbation in the following year. This suggests that using mere cell count to 
assess inflammation in clinical practice may still carry some value and help to 
phenotype asthma patients (203). Naturally, this is an observational finding that does 
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not obey the tight criteria of randomised controlled trials, and our finding has to be 
confirmed in randomised trials comparing different management strategies. 
Our proportion of eosinophilic asthma is greater than that found by McGrath et al. 
(140), as they only found eosinophilic asthma in 17–36% of patients. However, their 
study recruited patients highly selectively, as is usually the case in clinical drug trials, 
thereby excluding quite a proportion of patients seen in clinical practice (i.e. smokers, 
those poorly reversible to β2-agonists and those with co-morbidity), which was not 
the case in our field study. Of course, we can also speculate that compliance to ICS 
was better in patients described by McGrath et al. (140), which may have also 
resulted in lower proportions of eosinophilic asthma. It is worth noting that our 
proportion of non-eosinophilic versus eosinophilic asthma based on sputum analysis 
is rather similar to what was reported in another field study (13). 
In conclusion, concomitant systemic and bronchial eosinophilic inflammation 
contribute to poor asthma control. As there was dissociation between systemic and 
airway eosinophilic inflammation in 30% of patients, assessment of inflammation in 
both airways and peripheral blood provides additional information about asthma 
status. We believe our classification may be valid to start intervention studies using 
drugs mainly targeting either the airways or the blood compartment according to the 
patient’s profile.  
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4.6 Severe asthma (SA) subphenotypes  
4.6.1 Introduction 
After detailed assessment, 350 severe asthmatics that fulfilled the American Thoracic 
Society definition of refractory asthma (214) were recruited between March 2009 and 
January 2014 from 9 Belgian academic centres. 
The Belgian Registry is a secured web database and admits password-protected 
anonymised data, after fully-informed written consent. Individual centre data can be 
downloaded locally by registered users. 
The definition of severe asthma requires one major criterion: either treatment with 
continuous or near continuous (>50% of year) oral corticosteroids or a requirement 
for combination high-dose ICS (Beclomethasone or Budesonide > 1000 µg/d, 
Fluticasone > 500 µg/d) and long-acting β-2 agonists (LABA). The major criterion has 
to be associated with at least two minor criteria: need for additional daily controller 
medication in addition to ICS-LABA combinations (Leucotrienes antagonists (LTRA), 
theophylline), persistent airway obstruction (FEV1 <80% pred, PEF variability > 20%), 
asthma symptoms needing short-acting β2 agonist on a daily or near-daily basis, one 
or more urgent care visits for asthma per year, three or more oral corticosteroids 
bursts per year, prompt deterioration with < 25% reduction in oral or ICS use, or 
near-fatal asthma event in the past. 
The prerequisite for inclusion was age >18years, asthma follow-up by a respiratory 
physician for at least 12 months, education on the disease provided to the patient, 
and compliance thought to be satisfactory. 
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Exacerbation in the previous year was defined by a course of oral corticosteroids for 
at least 3 days in case of asthma worsening. Nasal polyps and sinusitis was 
diagnosed by Ear Nose and Throat specialists either by endoscopy or Sinus CT 
scanner. Gastro oesophageal reflux was diagnosed either by symptoms of heartburn 
at history taking or the presence of oesophagitis demonstrated by gastroscopy. 
4.6.2 Criteria for inflammatory phenotyping 
Patients underwent FENO measurement and sputum was only induced at Liege CHU 
with a success rate of 77%. In a subanalysis we identified patients with type2-high 
and type2-low inflammation according to the following criteria: sputum eosinophil 
count < or ≥3% (11), exhaled nitric oxide < or ≥27ppb (166) and blood eosinophil 
count < or ≥188/mm³.  
4.6.3 Results 
We recruited 350 SA as defined by the ATS (2000) criteria from 9 Belgian centres. 
From those patients, 333 are still defined as severe asthmatics according to 
ERS/ATS guidelines on severe asthma (2014) (93). The demographic, functional, 
clinical and inflammatory characteristics of the 350 severe asthmatics are 
summarised in Table 24.  
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Table 24. Patients characteristics of the Belgian SA cohort  
Patient characteristics  
N. 350 
Female (%) 57% 
Age 55 ± 0.8 
Age at onset 
     <12 years 
     12 – 40 years 
     >40 years 
 
32% 
36% 
31% 
Height, m 167 ± 0.5 
Weight, kg 75 ± 0.9 
BMI 26 (16 – 43) 
Smoking status 
     Never 
     Ex-smoker  
          (pack-years median IQR) 
     Current smokers  
          (pack-years median IQR) 
 
200 (57%) 
108 (31%) 
(15 (11-24)) 
40 (12%) 
(11 (10-15)) 
Atopy, % 70 
Current House environment (%) 
     Country side 
     Suburban area 
     City 
     Unknown 
 
39 
29 
31 
1 
Pre-BD FEV1, % pred  68 ± 1.2 
FVC, % pred  89 ± 1.1 
FEV1/FVC, %  63 ± 0.7 
FEV1Reversibility (% from baseline)  11 ± 0.8 
FRC (%) (n=271)  120 ± 2 
RV (%) (n=311) 140 ± 2.8 
TLC (%) (n=305) 102 ± 1.1 
DLCO (%) (n=273) 78 ± 1.2 
KCO (%) (n=273) 97 ± 1.3 
Airway inflammatory indices 
     FENO50 (ppb) (n=271) 
     Sputum eosinophil count (%) (n=86) 
     Sputum neutrophil count (%) (n=86) 
 
26 (4 – 250) 
7 (0 – 92) 
51 (0 – 99) 
Sputum inflammatory subphenotype (n=86) 
     Paucigranulocytic 
     Eosinophilic (≥3%) 
     Neutrophilic (≥76%) 
     Mixed granulocytic 
 
17% 
55% 
22% 
6% 
Serum IgE (kU/l) (n=295) 207 (2 – 10000) 
Blood eosinophils (%) (n=272) 3 (0 – 50) 
Blood eosinophils (/mm³) (n=272) 240 (0 – 3144) 
ACT (n=207) 13 ± 0.4 
ACQ (n=213) 2.57 ± 0.09 
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AQLQ (n=244) 4.14 ± 0.09 
ICS dose (BDP µg equivalent/d) 2000 (190 - 6000) 
LABA 91 
Anti-histamines, % 26 
LTRA, % 65 
Anti-cholinergics, % 28 
Anti-IgE, % 27 
Theophylline, % 22 
Maintenance oral corticosteroids, % 24 
Specific immunotherapy, % 0.6 
Comorbidities (%) 
     Rhinosinusitis % (Y/N/Ukn) 
     Gastrooesophageal reflux (Y/N/Ukn) 
     Nasal polyps (Y/N/Ukn) 
     Overweight (Y/N/Ukn) 
     Psychopathology (Y/N/Ukn) 
 
     Catamenial asthma (Y/N/Ukn) 
     Aspirin sensitive asthma (Y/N/Ukn) 
     Occupational asthma (Y/N/Ukn) 
     Churg Strauss syndrom (Y/N/Ukn) 
     ABPA (Y/N/Ukn) 
     Bronchiectasis (Y/N/Ukn) 
     Emphysema (Y/N/Ukn) 
 
49% (167/151/32) 
36% (124/205/21) 
19% (167/151/32) 
47% (162/173/15) 
19% (65/266/19) 
 
0.9% (3/340/7) 
8% (28/315/7) 
4% (15/328/7) 
3% (10/333/7) 
3% (11/332/7) 
16% (54/289/7) 
7% (24/319/7) 
Treatment of comorbidities 
     Proton pump inhibitors 
     Anti-depressive/ anxiolytics 
     Intranasal steroids 
 
39% 
17%/14% 
39% 
Oral steroids courses during previous yr 2.03 (0 – 7) 
Number of hospitalisations during previous yr 0.95 (0 – 7) (n=113) 
Number of hospitalization during the last three 
years 
1.7 (0 – 8) (n=103) 
 
4.6.3.1 Demographics and treatment characteristics 
Female was the predominant gender (57%) and mean age was 55 yrs. 31% of the 
severe asthmatics had late-onset asthma (starting after the age of 40). BMI was 
slightly increased (26kg/m²) and one-quarter of the patients had a BMI >30. 31% 
were ex-smokers (64% with at least 10 pack-yrs) while 12% were current smokers. 
The prevalence of atopy was 70%.  
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One third of Belgian SA lived in cities, one third in suburban areas while 39% lived in 
the country-side.  
In addition to high doses of ICS+LABA, 65% of the patients received anti-
leukotrienes. 24% of severe asthmatics were treated with chronic systemic 
corticosteroids on a daily basis, 26% with anti-histamines and 27% with anti-IgE. 
Theophylline was administered to 22% of the patients and 0.6% received specific 
immunotherapy.  
Educational level was low in the majority of patients with 6% leaving school after 
primary school, 21% after lower secondary school and 25% after higher secondary 
school. Only 16% of severe asthmatics were graduated from non-university post-
secondary school and 6% from university (Fig 23A). Data are unknown in one-quarter 
of the patients. 36% of SA were employed while 21% were retired (Fig 23B).   
Co-morbidities were highly prevalent and included chronic rhinosinusitis (49%), nasal 
polyposis (19%), oesophageal reflux (36%), being overweight and obese (47%) and 
depression (19%). Bronchiectasis diagnosed based on classical CT criteria were 
reported in 16% and aspirin-sensitive asthma in 8% of SA while occupational asthma  
(4%), Churg Strauss syndrome (3%), ABPA (3%) and catamenial asthma (0.9%) 
were less frequent. Emphysema was present in 24 SA (7%), with 42% of those 
patients being current smokers, 42% ex-smokers and 16% non-smokers. 
The number of oral steroid courses during the previous year was 2.03. The number 
of hospitalisations during the previous year and the last three years was 0.95 and 1.7 
respectively (Table 25). Patients with a history of hospitalisation due to asthma did 
not have predominant sputum inflammation feature or more severe airway 
obstruction. 
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Fig 23. Panel A. Education level in severe asthma in 
Belgium. Panel B. Employment status in severe 
asthmatics in Belgium. 
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Table 25. Number of hospitalisations and steroid bursts in Belgian severe asthmatics during 
the previous year. 
Number during the 
last year 
% of patients with 
hospitalisation (n=106) 
% of patients with systemic 
corticosteroid courses 
(n=344) 
0 40 (n=42) 26 (n=90) 
1 35 (n=37) 15 (n=53) 
2 19 (n=20) 16 (n=56) 
3 5 (n=5) 14 (n=48) 
>3 2 (n=2) 28 (n=97) 
 
4.6.3.2 Lung function 
Despite impaired flow rates (mean FEV1, 68%pred; FEV1/FVC ratio, 63%), only 65% 
of SA had post-bronchodilator FEV1/FVC ratio <70%. We found that 60% of SA had 
FEV1<80% and FEV1/FVC<70%. The mean reversibility was still 11% while patients 
were on long-acting β2 agonists. 36% of SA exhibited ≥12% FEV1 reversibility to 
400µg Salbutamol and 16% of SA had a reversibility ≥20%. 
Severe asthma was associated with significant air trapping. Despite normal total lung 
capacity (102%pred) there were signs of air trapping suggested by raised FRC 
(120% of predicted values) and RV (140% of predicted). DLCO was slightly impaired 
(78%) but KCO was well preserved (97% pred).   
4.6.3.3 Inflammatory characteristics 
The median FENO value was 26ppb (4 - 250ppb). The fraction of patients with 
FENO≥50ppb was 22% (Fig 24). 
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Fig 24. Panel A. Distribution of FENO in the population of 
severe asthmatics. 49% of SA had FENO levels higher 
than 27ppb suggestive of persistent sputum eosinophilic 
inflammation. Panel B. Distribution of blood eosinophils in 
severe asthmatics. 58% had blood eosinophil count 
≥188/mm³. 
 
The median blood eosinophil count was 240/mm³ (Fig 24). We found elevated blood 
eosinophil counts (>220/mm³) in 53% of SA. Importantly we demonstrated a 
significant correlation between blood eosinophil count (/mm³) and sputum eosinophil 
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count (%) (p-value <0.0001; r=0.53). The median sputum eosinophil count and 
sputum neutrophil count was 7% and 51% respectively.  
By constructing a ROC curve, we found that the blood eosinophil count was able to 
identify sputum eosinophil count ≥3% with the best cut-off point of 188/mm³ providing 
a 72% sensitivity and 73% specificity (n=80, AUC=0.745, Fig 25).  
 
 
Fig 25. ROC curve showing the best cut-off of blood 
eosinophil count to identify sputum eosinophil count ≥3% 
in SRA. Sensitivity 72.3%, specificity 72.7%, Cut-off: 
188/mm³, n=80. 
 
We found a modest but significant correlation between FENO and sputum eosinophil 
count (r=0.37, p<0.001) and between FENO and blood eosinophils (r=0.29, 
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p<0.0001). By constructing a ROC curve, we found that the best cut-off of FENO was 
28ppb to identify sputum eosinophil counts ≥3% in severe asthmatics. 
We assessed the proportion of patients exhibiting concordant and discordant blood 
and sputum eosinophilia. Blood eosinophilia ≥400/mm³ (10) and sputum eosinophil 
count ≥3% was found in 23% of the patients while exhibiting elevated sputum 
eosinophil count without increased blood eosinophil count was found in 35%. Normal 
blood and sputum eosinophil count was common (38%) while isolated elevation of 
blood eosinophil count was rare (4%). If we chose the threshold value of ≥300/mm³ 
as recommended by some authors (11), diffuse eosinophilic inflammation was found 
in 36% of the patients, isolated sputum eosinophilic inflammation was found in 24%, 
normal blood and sputum eosinophil count was common (33%), while isolated blood 
eosinophilia was rare (7%).  
4.6.3.4 Asthma control and quality of life 
Asthma was uncontrolled in 77% of severe asthmatics as defined by an ACQ score 
>1.5 and in 83% as defined by ACT <20.  
We found however that 8% had well-controlled severe asthma (ACQ <0.75) and that 
71% of those patients were women with a high proportion being employed (65%). 
None of these patients were current smokers (88% non-smokers, 12% former 
smokers). BMI was slightly lower (24kg/m²) than in the general SA population and 
atopy was more frequent (77%). Quality of life assessed by AQLQ was also better in 
this sub-population. They had a better lung function (FEV1 mean: 92%±1.2, 
FEV1/FVC: 70±0.9) and fewer signs of air trapping (RV:120±2.5, FRC: 113±2). Only 
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12% were treated with oral corticosteroids. They exhibited lower FENO levels (17(5-
76)) and lower blood eosinophil counts (120 (0-1200)).  
4.6.3.5 Relationship between lung function, inflammation, asthma control and 
quality of life  
Average AQLQ was 4.14 (1.2-7). We found a positive correlation between FEV1 and 
AQLQ (r=0.21, p<0.0001) and an inverse correlation between FEV1 and ACQ (r=-
0.49, p<0.0001). We did not find any significant correlation between blood 
eosinophils or sputum eosinophil count and AQLQ (r=-0.01, p=0.8; r=-0.06, p=0.58 
respectively) or between blood eosinophils or sputum eosinophils and ACQ (r=-0.02, 
p=0.8; r=0.06, p=0.57). We did not find any significant correlation between BMI and 
ACQ or AQLQ.  
4.6.3.6 Type 2-high versus type 2-low criteria for targeted therapy 
The median total serum IgE level was 207kU/l and 58% of SA with atopic status 
exhibited IgE levels between 76 and 700kU/l, the range to possibly consider 
treatment with omalizumab in Belgium (215). In non-atopic SA, 48% had IgE levels 
between 76 and 700kU/l. Detailed data on sensitisation were available in the Liege 
cohort (n=111) where 45% of SA were atopic to house dust mite, 39% to cat, 31% to 
dog, 29% to grass pollen, 23% to birch pollen, 21% to moulds and 12% to horse. 
According to Belgian’s reimbursement criteria, treatment with omalizumab could be 
proposed in 27% of SA in Liege. 
In the DREAM study (11), asthmatics had a history of 2 or more exacerbations 
requiring systemic corticosteroids in the previous year. Additionally, they had 
evidence of eosinophilic inflammation as shown by one or more criteria: a sputum 
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eosinophil count of ≥3%, FENO ≥50ppb, blood eosinophils ≥300/mm³ or prompt 
deterioration of asthma control after a 25% or less reduction in regular maintenance 
ICS or OCS. According to these criteria (11), 106 patients (30%) of this cohort could 
be eligible for anti-IL5 therapy.  
We further classified our SA into inflammatory phenotypes according to evidence of 
either sputum eosinophil count ≥3% or the presence of both FENO ≥27ppb and blood 
eosinophil count ≥188/mm³. We found that 57% of SA fulfilled those criteria (Fig 26). 
Eosinophilic SA was more frequently associated with chronic rhinosinusitis (65%) and 
nasal polyps (24%) in case of late-onset asthma compared to 52% and 18% in early 
onset asthma. 
 
Fig 26. Classification of SA in Type 2-high versus Type 2-low phenotype 
according to sputum eosinophil count (≥ or <3%), FENO levels (≥ or <27 
ppb), and blood eosinophil count (≥ or <188/mm³). SA were classified as 
Th2-high phenotype if induced sputum showed ≥3% eosinophils or FENO 
levels ≥27ppb and blood eosinophil count ≥188/mm³ while Type 2-low was 
chosen if induced sputum eosinophil count was <3% or FENO and Blood 
eosinophil count were <27ppb and <188/mm³ respectively. 169 patients were 
classified in eosinophilic and non-eosinophilic asthma according to this 
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definition and further characterised as early (<12yrs), intermediate (12-40yrs) 
or late onset (>40 yr). *181 patients were unclassified due to the lack of 
information on induced sputum, FENO or blood eosinophil count or 
discordant FENO and blood eosinophils information. 
4.6.3.7 Characteristics of patients according to Belgian region 
It should be noted that the 350 severe asthmatics were recruited from 9 Belgian 
centres including CHU Liege (32%), Ghent University Hospital (28%), CHU Mont-
Godinne (15%), Erasme (8%), Cliniques universitaires Saint-Luc (7%), CHU Vesale 
(6%), CHU St Pierre (3%), Brugman (1%) and UZ Leuven (<1%) (Fig 27). 
 
Fig 27. Proportion of patients recruited by the different Belgian centres. 
 
The three Belgian regions are Flanders (Dutch-speaking part), Wallonia (French- and 
German- speaking part) and Brussels (Dutch- and French- speaking part); patients’ 
characteristics were compared according to the region.  
We found higher numbers of patients with smoking history in Wallonia and Brussels 
than in Flanders (Table 26), the highest tobacco history was observed in Wallonia. 
Despite similar FEV1/FVC ratios, FEV1 was clearly more altered in patients from 
CHU Liege (n=111)
UZ Gent (n=99)
Mont-Godinne (n=52)
CUB Erasme (n=28)
UCL St-Luc (n=25)
CHU Vesale (n=19)
CHU St-Pierre (n=9)
CHU Brugmann (n=5)
UZ Leuven (n=2)
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Wallonia and Brussels than those from Flanders. Reversibility to β2-agonists and 
signs of air trapping were significantly higher in Brussels and Wallonia than in 
Flanders. Asthma control and quality of life was better in patients from Flanders than 
in Wallonia and Brussels. 
We also found discrepancies concerning the treatment prescribed in the different 
regions. In Flanders, there were fewer patients prescribed with leukotriene receptor 
antagonists but higher frequency with LAMA and oral corticosteroids. Anti-IgE and 
Theophylline use was significantly higher in Brussels.  
Gastro-oesophageal reflux was frequent in SA patients from Wallonia. Overweight 
was encountered significantly less in Brussels. We found less psychopathology and 
less emphysema in Flanders. The number of hospitalisations during the last three 
years was highest in Wallonia. 
Table 26. Patient characteristics of the SA classified according to the region of recruitment. 
 Wallonia Flanders Brussels 
N. 182 101 67 
Female (%) 59 53 58 
Age 54±1 57±1.5 56±2 
Age at onset           
    <12 years 
    12 – 40 years 
     >40 years 
 
34% 
36% 
30% 
 
33% 
36% 
31% 
 
34% 
35% 
31% 
Height, m 167 ± 0.7 168 ± 0.9 166 ± 1.2 
Weight, kg 76 ± 1.2 76 ± 1.4 72 ± 2.1 
BMI 26 (17 – 43) 26 (18 – 40) 25 (16-39) 
Never smoker 
Ex-smoker (pack-years 
median IQR) 
Current smokers       
(pack-years median 
IQR) 
50% 
39% 
(15 (6 – 25)) 
17% 
(15 (9 - 32)) 
 
75%*** 
22%** 
(10 (8 – 20)) 
3%** 
(5)* 
61% 
27 % 
(10 (5 – 19))
§
 
12%
§
 
(19 (10 – 30)) 
Atopy, % 70 63 78 
House environment  
     Country side 
     Suburban area 
     City 
 
28% 
24% 
48% 
 
27% 
51%*** 
22%*** 
 
35% 
11%
§###
 
54%
###
 
Pre-BD FEV1, % pred  62 ± 1.4 82 ± 2.3*** 64 ± 2.1
###
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FVC, % pred  81 ± 1.3 105 ± 1.9*** 85 ± 2
###
 
FEV1/FVC, %  62 ± 0.8 65 ± 1.3 63 ± 1.5 
FEV1 Reversibility (% 
from baseline)  
11 ± 0.9 6 ± 1*** 16 ± 3.5
###
 
FRC (%)  120 ± 2.8 115 ± 3.1 128 ± 6.1
#
 
RV (%)  142 ± 4 127 ± 4.2* 153 ± 7
##
 
TLC (%)  107 ± 1.5 102 ± 1.8 104 ± 3.7 
DLCO (%) 76 ± 1.7 85 ± 1.5** 71 ± 3.7
§§###
 
KCO (%)  98 ± 1.7 101 ± 1.8 85 ± 4
##
 
FENO, ppb 27 (4-250) 21 (6-200) 29 (5-208) 
 
Serum IgE (kU/l)  216 (2-10000) 160 (4-5421) 260 (2-5767) 
Blood eosinophils (%)  3 (0-38) 3 (0-50) 4 (0-21) 
Blood eosinophils 
(/mm³)  
232 (0-3144) 250 (0-1460) 260 (0-1677) 
ACT  13 ± 0.4 13 ± 1.9 14 ± 0.9 
ACQ  2.82 ± 0.1 1.54 ± 0.2*** 2.72 ± 0.2
###
 
AQLQ  3.84 ± 0.1 5.16 ± 0.2*** 4.15 ± 0.2
###
 
ICS dose (BDP µg 
equivalent/d) 
2000 (200-6000) 2000 (770-6000) 2000 (190-4000)
##
 
Anti-histamines, % 28 33 14
#
 
LTRA, % 71 49** 71
#
 
LAMA, % 27 39 19
#
 
Anti-IgE, % 24 18 46
§§§###
 
Theophylline, % 15 22 29
§
 
Maintenance oral 
corticosteroids, % 
20 34* 19 
Specific 
immunotherapy, % 
1.3 0 0 
Rhinosinusitis,%  
GERD,% 
Nasal polyps,%  
Overweight,%      
Psychopathology,%  
Catamenial,%  
Aspirin sensitive, % 
Occupational, %  
Churg Strauss, % 
ABPA,%       
Bronchiectasis,%  
Emphysema,%  
53 
49 
20 
53 
25 
2 
6 
4 
2 
4 
17 
12 
42 
19*** 
17 
50 
7*** 
0 
12 
3 
6 
2 
15 
1** 
47 
28
§§§
 
17 
27
§§§##
 
20
# 
0 
8 
6 
0 
3 
13 
3 
Oral steroids courses 
during previous yr 
 
2.1/patient/yr 
 
1.9/patient/yr 
 
1.8/patient/yr 
Number of 
hospitalisation during 
previous yr 
 
0.38/patient/yr 
 
0.21/patient/yr 
 
0.21/patient/yr 
Number of 
hospitalisation during 
the last three years 
 
0.67/patient/yr 
 
0.21/patient/yr* 
 
0.41/patient/yr 
*for comparisons between Wallonia and Flanders. #for comparisons between Flanders and 
Brussels. §for comparisons between Wallonia and Brussels. GERD: gastro-oesophageal 
reflux. 
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4.6.4 Discussion 
Our data confirm that the majority of severe asthmatics are female and atopic (216). 
Moreover we have shown that asthma started after the age of 12 in two-thirds of 
SRA, and that SRA exhibited increased airway granulocytic inflammation compared 
to a general population of asthmatics (128). Dominant co-morbidities were chronic 
rhinosinusitis, overweight and gastrooesophageal reflux. Type2-high and Type2-low 
SA were diagnosed based on induced sputum, blood eosinophil count, IgE and 
FENO levels. A trait suggesting type2-high was identified in the majority of SA 
despite treatment with high doses of ICS (and oral corticoids in a subgroup). 
4.6.4.1 Demographic and general clinical data 
Our data confirm the usual female preponderance (110;111;217;218). In comparison 
with a general population of asthmatics (219), SRA was rather similar in age (55 vs 
52). Late-onset asthma, starting after the age of 40, was observed in 31% of patients. 
The proportion of current smokers was higher than that observed in the UK registry 
(111) (12% vs 6%) while 31% of our population recognised past smoking history 
(similar to the UK registry). Thomson’s study (220) showed similar data with 9% of 
British severe asthmatics being current smokers, while 28% were ex-smokers and 
62% never-smokers. In this study, current smokers had poorer asthma control and 
more unscheduled health care visits and rescue courses of oral steroids than ex-
smokers or never-smokers. Their inflammatory profiles in sputum and blood also 
differed.  
BMI was slightly increased but remained in the non-obese range in the majority of 
patients (only one-quarter had BMI > 30) and was similar to that observed in the 
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general population of asthmatics (219), in the UK registry (111), ENFUMOSA (107) 
and BIOAIR studies (108).  
Severe asthmatics in Belgium have a rather low level of education with only 22% 
having graduated from post-secondary school education. Our interpretation is that 
asthmatics with low level of education are more prone to be exposed to noxious 
particles, massive allergen amount in their daily life because being less cautious in 
taking care of their health. Less than 40% of severe asthmatics are still professionally 
active. This was similar to what was observed in the UK where 53.4% were not 
working (111); the ENFUMOSA study (221) concluded that fewer severe asthma 
patients than mild asthma patients were currently employed.  
The patients with SA that were entered in the registry were more severe in Wallonia 
and Brussels. The more frequent smoking history (222) and co-morbidities (223) 
observed in Wallonia may contribute to severity and hospital admissions observed in 
this region.  
4.6.4.2 Treatment and co-morbidities 
In addition to high doses ICS-LABA, SRA in Belgium received LTRA and omalizumab 
more frequently than in the UK (111) while theophylline and oral corticosteroids were 
less commonly encountered than in the UK registry and ENFUMOSA. The higher 
number of anti-IgE treated patients in our registry is probably due to the inclusion of a 
high number of Belgian severe refractory asthmatics in the PERSIST study (224). For 
the management of co-morbidities, intranasal corticosteroids and proton pump 
inhibitors (PPI) were more frequently prescribed in Belgium than in the UK (111). 
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The number of oral steroids courses during the year preceding inclusion in the SRA 
was lower than that observed in the UK register (111) while the number of 
hospitalisations was higher. 
The dominant co-morbidities encountered in the Belgian severe asthma population 
were rhinosinusitis, overweight and gastrooesophageal reflux. The proportions were 
similar those previously reported (111), except for chronic rhinosinusitis that was 
more frequently encountered in Belgium. The treatment of rhinosinusitis by nasal 
corticosteroids is in accordance with the high proportion of rhinitis observed in a large 
population of asthmatics in Belgium (225). We found a similar proportion of 
occupational asthma and aspirin-sensitive asthma in our cohort as compared to the 
UK cohort (111). 
4.6.4.3 Lung function 
Overall there was a moderate obstructive airway pattern. The obstruction level was 
similar to ENFUMOSA (107) and the UK register (111), but lower than in the SARP 
study (110). Surprisingly, several patients with normal FEV1 were included in the 
registry due to high respiratory symptoms despite high-dose ICS. They are patients 
who still report symptoms and bronchodilator use despite good airway function. 
Although we cannot exclude that these patients exhibit persistent BHR, they might 
have ‘discordant disease’ (6) as their indices of airway inflammation were low 
(median FENO 22ppb, median sputum eosinophils 2.4%). 59% of these SA had 
obesity and late-onset disease (>40yrs) with characteristics similar to the ‘obese non-
eosinophilic’ asthma reported by Haldar et al. As in the UK registry (111) and 
ENFUMOSA study (107), the coefficient transfer was well-preserved in our 
population, which can be considered as a sign that our asthmatics are very different 
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from COPD patients even if the majority of our patients displayed fixed airway 
obstruction. The normal KCO suggests a preserved alveolocapillary membrane. We 
confirmed that severe asthma is associated with significant increase in air trapping 
with normal total lung capacity suggesting involvement of small airways (89;110;205).  
4.6.4.4 Inflammatory subphenotypes 
The frequency of atopy remained high despite two-thirds of SRA experiencing the 
onset of asthma after the age of 12. Atopy was similar to that observed in SARP 
study (110) but higher than in the BIOAIR study (108), ENFUMOSA (107) and the UK 
registry (111). SARP data and ours are based on skin prick tests and/or specific IgE 
level while in the UK registry it was based on the history, which may have led to 
underestimation. 
The median FENO value is in the lower part of the grey zone (25-50ppb (153)) in 
severe asthma. This is probably due to higher doses of inhaled corticosteroids in this 
sub-population. This suggests the persistence of an airway inflammatory process 
since we were able to show that in patients receiving high-dose ICS the FENO 
threshold predicting sputum eosinophil count ≥3% was shown to be 27ppb (166). 
49% of severe asthmatics exhibited FENO levels >27ppb suggesting an eosinophilic 
phenotype. As compared to the UK register (111), SARP (110) and BIOAIR (108), 
FENO levels were lower in our register.  
Our median blood eosinophil count was slightly lower than that observed in the UK 
register (111). The blood eosinophil count threshold that best predicts the presence 
of uncontrolled airway eosinophilia in SA was found to be 188/mm³. According to this 
threshold, 58% exhibited eosinophilic asthma. 
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Asthma was uncontrolled in 77% of severe asthmatics according to ACQ. The 8% 
well-controlled severe asthmatics were non-smoking patients with a higher rate of 
atopy, receiving high doses of corticosteroids and exhibiting less severe airway 
obstruction and fewer respiratory symptoms. They had less intense eosinophilic 
inflammation.  
4.6.4.5 Correlation between clinical and inflammatory data 
We found a correlation between asthma control and airway calibre, a fact that has 
already been observed in asthma in general (226;227). There was a weak correlation 
between quality of life and airway calibre. A similar correlation between FEV1 and 
AQLQ has already been demonstrated in a large population of persistent asthmatics 
(228). We did not find any significant correlation between systemic eosinophilic 
inflammation and asthma control or quality of life. In a previous study conducted in a 
large population of unselected asthmatics (219), we did not find any significant 
correlation between ACQ and blood eosinophil count while there was a weak 
correlation between ACQ and sputum eosinophil count. The fact that we did not find 
any correlation between blood eosinophil count or sputum eosinophil count and 
AQLQ is in line with the DREAM study, as anti-IL5 therapy was able to decrease 
sputum and blood eosinophil count but was not associated with an improvement in 
AQLQ (229) in severe eosinophilic asthmatics compared with placebo.  
BMI was correlated neither with ACQ nor with AQLQ in our severe asthma 
population. Median BMI in our Belgian severe asthma population is rather similar to 
BMI found in a general population of asthmatics (128;219). Lavoie et al. previously 
failed to find any association with asthma severity, which is consistent with the 
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present findings (230). The impact of BMI is probably lower in severe asthmatics as 
there are several other factors influencing asthma control in this population. 
4.6.4.6 Therapeutic implications 
We found elevated levels of IgE in our population of severe asthmatics whatever the 
atopic status. For the management of severe asthma in Belgium, the only biological 
treatment already commercially available is anti-IgE, reimbursed in case of 
sensitisation to perennial allergen and a level of IgE between 76 and 700kU/l. The 
median IgE was higher in our register than that observed in the UK register (111), 
ENFUMOSA (107) and SARP (110).  
The majority of patients have residual eosinophilic inflammation both at systemic and 
airway level and are therefore potential candidates for anti-IL5 treatment. In the 
DREAM study (11), asthmatics had a history of two or more exacerbations requiring 
systemic corticosteroids in the previous year. Additionally, they had evidence of 
eosinophilic inflammation as shown by one or more criteria: a sputum eosinophil 
count of ≥3%, FENO of 50ppb or more, blood eosinophils of 300/mm³ or more, or 
prompt deterioration of asthma control after a 25% or less reduction in regular 
maintenance ICS or OCS. We identified 30% of potential candidates for anti-IL5 
therapy according to DREAM criteria (11). However taking into account the adapted 
threshold (for FENO and blood eosinophil count) to identify eosinophilic inflammation 
in asthmatics treated with high doses ICS, 57% of patients had eosinophilic asthma.  
Although the mechanism of action of bronchial thermoplasty is not currently 
completely understood, this bronchoscopy technique seems to act on smooth muscle 
mass. Thermoplasty could emerge as a therapeutic option in SA who exhibit high 
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bronchodilatation after salbutamol (16% of SA in our registry). The role of macrolides 
in non-eosinophilic severe asthma (25) remains to be clarified in larger studies. 
For the recruitment of Belgian SRA, we followed 2000 ATS criteria (214) because the 
collection of data started in 2009. Our study limitations are the limited number of 
patients with detailed allergic characteristics and induced sputum analysis and the 
recruitment at tertiary care University hospitals with potential selection bias. 
 
4.6.5 Conclusion 
In this Belgian cohort of patients with SA, we show that atopic background and 
eosinophilic inflammation represent the predominant features. Findings are 
consistent with other European and American registries, and will help to identify 
candidates for upcoming targeted therapeutic approaches. Further studies are also 
needed to clarify whether particular endotypes could be identified in this 
heterogeneous group of asthma patients with severe disease that is refractory to 
current therapies.   
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5 Chapter 5. General discussion and perspectives 
 
The different phenotypes of bronchial asthma described in the literature confirm the 
heterogeneous nature of the disease. This heterogeneity is reflected by various 
clinical characteristics according to asthma subtypes defined by either inflammation, 
demographic and functional parameters. The classification of asthmatics in different 
inflammatory phenotypes has therapeutic implications. The eosinophilic phenotype 
has been shown to be corticosensitive while non-eosinophilic asthma is not improved 
by corticosteroids in short term studies. In neutrophilic and paucigranulocytic asthma, 
other treatment such as long-acting β2-agonists, long-acting anti-muscarinic agents 
or macrolides could be good candidates for targeted treatment. We are happy to see 
that the new GINA guidelines recognise the utility of induced sputum in specialised 
centres to guide treatment in patients who are uncontrolled despite high doses of 
inhaled corticosteroids associated to other controller therapy.  
 
We have confirmed on a large asthmatic cohort the heterogeneity of airway 
inflammation and provided proportions of each inflammatory phenotype as 
encountered in clinical practice at a university hospital. The most frequently observed 
inflammatory subtypes were eosinophilic and paucigranulocytic phenotypes. 
This classification remains interesting as it shows that eosinophilic asthma is more 
prone to exacerbations.  
 
Applying Simpson classification we have shown that factors associated with 
eosinophilic inflammation differ from those associated with neutrophilic phenotype. 
Eosinophilic asthma is associated with blood eosinophils, elevated FENO levels, high 
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blood IgE levels and a low FEV1/FVC ratio, while neutrophilic asthma was associated 
with higher FRC and age. However asthma control was rather similar whatever the 
sputum inflammatory phenotype. The link between neutrophils or eosinophils and 
asthma severity remains controversial. Without denying the interest of the Simpson 
classification, we have proposed a new way to classify asthma. It seems interesting 
to us to analyse eosinophilic inflammation more in depth by confronting systemic and 
airway eosinophilia. We have identified a subgroup of asthmatics including a majority 
of males, exhibiting both blood and airway eosinophilic inflammation more prone to 
exacerbations, expressing lower asthma control and poorer lung function. 
Interestingly, this group had more often nasal polyposis. Our new classification allows 
identification of a subgroup of asthmatics who are poorly controlled and at risk of 
recurrent exacerbations. We think our classification has greater clinical impact than 
just looking at airway inflammation, and reveals the relationship between eosinophilic 
inflammation and asthma severity. Looking at both inflammatory sites is valid to start 
intervention studies as the novel biotherapies such anti-IL5 have been developed 
based on inflammatory processes. We believe our new classification is timely as we 
have now available treatments targeting either airway (ICS) or systemic (OCS, anti-
IL5) eosinophilic inflammation. ICS were shown to be very potent in decreasing 
airway eosinophilia while their effect on blood eosinophil count was limited. Anti-IL5 
therapy is particularly efficient in those patients with high blood eosinophils by 
reducing exacerbations (15;16;231-235).  
 
We have also described the Belgian severe asthma population and their 
inflammatory characteristics. What is striking is that the proportion of 
paucigranulocytic asthma is very low, supporting the role of uncontrolled airway 
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inflammation as a key factor in determining asthma severity. Another finding of our 
study is that residual eosinophilic inflammation is still seen in many severe patients. 
This highlights the need for add-on therapy to inhaled corticosteroids to combat 
eosinophilic inflammation. One-fifth of the patients had heavy airway neutrophilic 
inflammation. Our Belgian registry will serve as a pool of patients that can be 
included in clinical studies on new targeted biotherapies or in studies designed to 
understand the pathophysiology of severe asthma.  
We have been able to show that FENO and blood eosinophil thresholds that predict 
airway eosinophilic inflammation may be influenced by the dose of inhaled 
corticosteroids and smoking history for the former. Consequently our data show that 
FENO and blood eosinophil levels that predict airway eosinophilic inflammation are 
lower in severe asthmatics than in mild to moderate patients. 
While FENO and blood eosinophils may suggest the presence of airway eosinophilic 
inflammation, we currently lack of markers for identifying neutrophilic inflammation. 
Our work has identified potential markers for airway neutrophilic inflammation. The 
usefulness of biomarkers (VOCs) identified in exhaled air has to be confirmed in a 
prospective validation study. In the future we would like to investigate if FENO could 
provide complementary information to exhaled VOCs in a combined model that could 
be even more powerful. 
 
The future for asthma management may be that patients use small devices to detect 
VOCs such as the glucometers used for diabetes, to receive immediate information 
on inflammatory subtypes of the disease in order to adapt their treatment to reach 
asthma control with reduction of future risk. In chronic obstructive pulmonary disease 
(COPD) several phenotypes have also been identified (236), and it has been shown 
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that a small proportion of these COPD patients exhibit eosinophilic inflammation 
during and even outside the exacerbation. Perhaps we will be able to go one step 
further by discarding the labels ‘asthma’ and ‘COPD’ in order to focus on eosinophilic 
versus non-eosinophilic airway disease, and choosing and adjusting treatment 
accordingly.  
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